

Approved



**Malawi**  
**Country Operational Plan**  
**FY 2018**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		625,022		625,022	367,400	992,422
USAID		47,886,777	15,500,000	63,386,777	0	63,386,777
DOD		2,563,158		2,563,158	69,568	2,632,726
PC		1,516,533		1,516,533	376,520	1,893,053
HHS/CDC	1,512,500	67,184,127		68,696,627	0	68,696,627
State/AF		742,825		742,825	33,418	776,243
HHS/HRSA				0	100,252	100,252
<b>Total</b>	<b>1,512,500</b>	<b>120,518,442</b>	<b>15,500,000</b>	<b>137,530,942</b>	<b>947,158</b>	<b>138,478,100</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							Total
	State	DOD	HHS/CDC	HHS/HRSA	PC	State/AF	USAID	
CIRC		484,176	4,382,538	0	0	0	11,866,194	16,732,908
HBHC		145,422	620,930	0	0	0	4,054,675	4,821,027
HKID	0	0	0	0	7,500	0	6,749,877	6,757,377
HLAB		0	1,751,874	0	0	0	0	1,751,874
HMBL		0	605,738	0	0	0	0	605,738
HMIN		0	0	0	0	0	0	0
HTXD		0	0	0	0	0	0	0
HTXS	146,795	925,649	32,047,117	0	0	542,825	14,238,521	47,900,907
HVAB		60,000	982,676	0	0	0	2,695,603	3,738,279
HVCT		233,487	7,312,757	0	0	100,000	6,641,259	14,287,503
HVMS	478,227	34,502	3,445,031		1,508,533		2,519,080	7,985,373

Approved



HVOP		151,382	561,250	0	500	100,000	4,282,227	<b>5,095,359</b>
HVSI		200,000	1,698,565	0	0	0	340,740	<b>2,239,305</b>
HVTB		46,500	3,103,283	0	0	0	2,520,262	<b>5,670,045</b>
IDUP		0	0	0	0	0	0	<b>0</b>
MTCT		45,000	3,115,799	0	0	0	28,085	<b>3,188,884</b>
OHSS		0	796,986	0	0	0	1,572,120	<b>2,369,106</b>
PDCS		0	1,587,411	0	0	0	2,813,755	<b>4,401,166</b>
PDTX	0	237,040	6,684,672	0	0	0	3,064,379	<b>9,986,091</b>
	<b>625,022</b>	<b>2,563,158</b>	<b>68,696,627</b>	<b>0</b>	<b>1,516,533</b>	<b>742,825</b>	<b>63,386,777</b>	<b>137,530,942</b>



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount
HBHC	4,613,350
HKID	6,436,360
HVTB	5,502,667
PDCS	4,141,489
<b>Total Technical Area Planned Funding:</b>	<b>20,693,866</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount
HLAB	1,558,107
HVSI	1,174,990
OHSS	1,991,112
<b>Total Technical Area Planned Funding:</b>	<b>4,724,209</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount
CIRC	16,519,215
HMBL	580,000
HMIN	0
HVAB	3,554,177
HVCT	13,952,137
HVOP	4,884,108
IDUP	0
MTCT	3,096,014
<b>Total Technical Area Planned Funding:</b>	<b>42,585,651</b>



Approved



**Technical Area: Treatment**

<b>Budget Code</b>	<b>Budget Code Planned Amount</b>
HTXD	0
HTXS	45,336,718
PDTX	9,357,914
<b>Total Technical Area Planned Funding:</b>	<b>54,694,632</b>

## Technical Area Summary Indicators and Targets

Indicator Number	Label	2019
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	95 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	473,553
	Number of new ANC and L&D clients	498,530
	By Age (Denominator): 10-14	1,155
	By Age (Denominator): <15-19	112,421
	By Age (Denominator): 20-24	175,403
	By Age (Denominator): 50+	391
	By Number of known positives: 10-14	61
	By Number of known positives: 15-19	5,546
	By Number of known positives: 20-24	8,659
	By Number of known positives: 50+	15
	By Number of new positives: 10-14	26
	By Number of new positives: 15-19	3,358
	By Number of new positives: 20-24	5,247
	By Number of new positives: 50+	7
	By Number of new negative: 10-14	1,009
	By Number of new negative: 15-19	97,866
By Number of new negative: 20-24	152,680	



	By Number of new negative: 50+	352
	By Age (Numerator): 10-14	1,093
	By Age (Numerator): 15-19	106,781
	By Age (Numerator): 20-24	166,585
	By Age (Numerator): 50+	389
	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	170,216
	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	31,486
	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	6,499
	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	959
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Known at Entry Positive	8,409
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Negative	148,163
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Positive	5,091
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Known at Entry Positive	1,562
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Negative	27,429
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Positive	948
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Known at Entry Positive	338



	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	5,661
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	197
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	51
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	839
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	27
	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	161,658
	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	29,938
	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	6,183
	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	923
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	86 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	57,465
	Number of new ANC and L&D clients	66,809
	By Age (Denominator): 10-14	127



	By Age (Denominator): 15-19	15,204
	By Age (Denominator): 20-24	23,745
	By Age (Denominator): 50+	19
	By known positives: 15-19	447
	By known positives: 20-24	695
	By new positives: 15-19	298
	By new positives: 20-24	463
	By new negatives: 10-14	109
	By new negatives: 15-19	12,252
	By new negatives: 20-24	19,126
	By new negatives: 50+	12
	By Age (Numerator): 10-14	118
	By Age (Numerator): : 15-19	12,950
	By Age (Numerator): 20-24	20,312
	By Age (Numerator): 50+	13
	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	23,034
	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	3,801
	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	776
	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	103
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 25-29, Female, Known at Entry Positive	679
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 25-29, Female, Newly Identified Negative	18,572
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 25-29, Female, Newly Identified Positive	446
	PMTCT_STAT_N_TA_Age_Sex_K	106



	nownNewResult 30-34, Female, Known at Entry Positive	
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 30-34, Female, Newly Identified Negative	3,410
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 30-34, Female, Newly Identified Positive	63
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 35-39, Female, Known at Entry Positive	6
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 35-39, Female, Newly Identified Negative	694
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 35-39, Female, Newly Identified Positive	2
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 40-49, Female, Newly Identified Negative	86
	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	19,629
	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	3,616
	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	738
	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	89
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	8 %
	Number of HIV-positive pregnant women who received ART to	37,534



	reduce risk of mother-to-child-transmission (MTCT) during pregnancy	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	473,553
	New on ART	14,187
	Already on ART at beginning of current pregnancy	23,347
PMTCT_ART_TA	PMTCT_ART_TA Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	5 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,138
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	57,465
	New on ART	1,260
	Already on ART at beginning of current pregnancy	1,878
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	145,035
	By Age: 10-14	29,251
	By Age: 15-19	57,794
	By Age: 20-24	29,392



	By Age: 25-29	14,181
	By Age: 50+	1,289
	By circumcision technique: Surgical VMMC	140,957
	By circumcision technique: Device-based VMMC	4,078
	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	4,376
	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	4,376
	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	4,376
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,060
	Female 15-19	234
	Female 20-24	518
	FSW	1,060
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	140
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	112
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	28
	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	28
PP_PREV_DSD	PP_PREV_DSD Percentage of the	n/a





	target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	299,968
	Age/sex: 10-14 Male	7,819
	Age/sex: 15-19 Male	9,663
	Age/sex: 20-24 Male	13,428
	Age/sex: 50+ Male	856
	Age/sex: 10-14 Female	25,589
	Age/sex: 15-19 Female	57,277
	Age/sex: 20-24 Female	60,024
	Age/sex: 50+ Female	429
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	8,790
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	20,423
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	11,018
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	22,943
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	11,628
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	21,493
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	7,833
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	20,752



PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0
	Age/sex: 10-14 Male	0
	Age/sex: 15-19 Male	0
	Age/sex: 20-24 Male	0
	Age/sex: 50+ Male	0
	Age/sex: 10-14 Female	0
	Age/sex: 15-19 Female	0
	Age/sex: 20-24 Female	0
	Age/sex: 50+ Female	0
	PP_PREV_N_TA_Age_Sex_v2 25-29, Female	0
	PP_PREV_N_TA_Age_Sex_v2 25-29, Male	0
	PP_PREV_N_TA_Age_Sex_v2 30-34, Female	0
	PP_PREV_N_TA_Age_Sex_v2 30-34, Male	0
	PP_PREV_N_TA_Age_Sex_v2 35-39, Female	0
	PP_PREV_N_TA_Age_Sex_v2 35-39, Male	0
	PP_PREV_N_TA_Age_Sex_v2 40-49, Female	0
	PP_PREV_N_TA_Age_Sex_v2	0



	40-49, Male	
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	27,238
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	36
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,042
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet	299



	the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	14,546
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	8,315
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	193,807
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	82
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	80
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,648
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	88
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	2,464
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	52
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,648



	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	88
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	2,464
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	52
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	7
	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	176
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	4
	Service Delivery Point (Facility) Inpatient: <1, Negative	42
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	420
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	1
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,232
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	8
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	1,195
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	9
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,843
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	74



Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	3,478
Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	57
Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,869
Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	76
Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	3,511
Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	58
Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	138
Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	6
Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	259
Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	4
Service Delivery Point (Facility) Other PITC: <1, Negative	676
Service Delivery Point (Facility) Other PITC: <1, Positive	3
Service Delivery Point (Facility) Other PITC: 1-9, Negative	5,570
Service Delivery Point (Facility) Other PITC: 1-9, Positive	106
Service Delivery Point (Facility) Pediatric : <5 Negative	4,599
Service Delivery Point (Facility) Pediatric : <5 Positive	45



	Service Delivery Point (Facility) TB: 15-19, Female, Negative	37
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	102
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	37
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	102
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	34
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	32
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	926
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	124
	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,219
	Service Delivery Point (Facility) Index: 15-19, Male, Positive	146
	Service Delivery Point (Facility) Index: 20-24, Female, Negative	926
	Service Delivery Point (Facility) Index: 20-24, Female, Positive	124
	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,219
	Service Delivery Point (Facility) Index: 20-24, Male, Positive	146
	Service Delivery Point (Facility) Index: 50+, Female, Negative	2
	Service Delivery Point (Facility) Index: 50+, Male, Negative	187
	Service Delivery Point (Facility) Index: 50+, Male, Positive	31



	Service Delivery Point (Facility) Index: <1, Negative	14
	Service Delivery Point (Facility) Index: 1-9, Negative	171
	Service Delivery Point (Facility) Index: 1-9, Positive	5
	Service Delivery Point (Facility) ANC: 10-14, Negative	3,547
	Service Delivery Point (Facility) ANC: 10-14, Positive	61
	Service Delivery Point (Facility) ANC: 15-19, Negative	5,578
	Service Delivery Point (Facility) ANC: 15-19, Positive	119
	Service Delivery Point (Facility) ANC: 20-24, Negative	8,862
	Service Delivery Point (Facility) ANC: 20-24, Positive	197
	Service Delivery Point (Facility) ANC: 50+, Positive	1
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	619
	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	1
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	605
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	8,041
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	495
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	14,958
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	401





Service Delivery Point (Facility) VCT: 20-24, Female, Negative	8,041
Service Delivery Point (Facility) VCT: 20-24, Female, Positive	495
Service Delivery Point (Facility) VCT: 20-24, Male, Negative	14,958
Service Delivery Point (Facility) VCT: 20-24, Male, Positive	401
Service Delivery Point (Facility) VCT: 50+, Female, Negative	149
Service Delivery Point (Facility) VCT: 50+, Female, Positive	1
Service Delivery Point (Facility) VCT: 50+, Male, Negative	702
Service Delivery Point (Facility) VCT: 50+, Male, Positive	26
Service Delivery Point (Facility) VCT: <1, Negative	348
Service Delivery Point (Facility) VCT: 1-9, Negative	2,852
Service Delivery Point (Facility) VCT: 1-9, Positive	29
HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Female, Negative	380
HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Female, Positive	36
HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Male, Negative	1,130
HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Male, Positive	77
HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Female, Negative	332
HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Female, Positive	47



HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Male, Negative	969
HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Male, Positive	206
HTS_TST_N_TA_Index_Age_Sex_ Result 35-39, Female, Negative	244
HTS_TST_N_TA_Index_Age_Sex_ Result 35-39, Female, Positive	45
HTS_TST_N_TA_Index_Age_Sex_ Result 35-39, Male, Negative	836
HTS_TST_N_TA_Index_Age_Sex_ Result 35-39, Male, Positive	215
HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Female, Negative	119
HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Female, Positive	63
HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Male, Negative	1,070
HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Male, Positive	436
HTS_TST_N_TA_Inpat_Age_Sex_ Result 25-29, Female, Negative	892
HTS_TST_N_TA_Inpat_Age_Sex_ Result 25-29, Female, Positive	25
HTS_TST_N_TA_Inpat_Age_Sex_ Result 25-29, Male, Negative	1,000
HTS_TST_N_TA_Inpat_Age_Sex_ Result 25-29, Male, Positive	7
HTS_TST_N_TA_Inpat_Age_Sex_ Result 30-34, Female, Negative	803
HTS_TST_N_TA_Inpat_Age_Sex_ Result 30-34, Female, Positive	34
HTS_TST_N_TA_Inpat_Age_Sex_ Result 30-34, Male, Negative	856



HTS_TST_N_TA_Inpat_Age_Sex_	48
Result 30-34, Male, Positive	
HTS_TST_N_TA_Inpat_Age_Sex_	581
Result 35-39, Female, Negative	
HTS_TST_N_TA_Inpat_Age_Sex_	31
Result 35-39, Female, Positive	
HTS_TST_N_TA_Inpat_Age_Sex_	733
Result 35-39, Male, Negative	
HTS_TST_N_TA_Inpat_Age_Sex_	54
Result 35-39, Male, Positive	
HTS_TST_N_TA_Inpat_Age_Sex_	329
Result 40-49, Female, Negative	
HTS_TST_N_TA_Inpat_Age_Sex_	47
Result 40-49, Female, Positive	
HTS_TST_N_TA_Inpat_Age_Sex_	946
Result 40-49, Male, Negative	
HTS_TST_N_TA_Inpat_Age_Sex_	142
Result 40-49, Male, Positive	
HTS_TST_N_TA_MN_Age_Sex_R	85
esult <5, Unknown Sex, Negative	
HTS_TST_N_TA_OtPITC_Age_Se	1,097
x_Result 25-29, Female, Negative	
HTS_TST_N_TA_OtPITC_Age_Se	27
x_Result 25-29, Female, Positive	
HTS_TST_N_TA_OtPITC_Age_Se	1,449
x_Result 25-29, Male, Negative	
HTS_TST_N_TA_OtPITC_Age_Se	13
x_Result 25-29, Male, Positive	
HTS_TST_N_TA_OtPITC_Age_Se	951
x_Result 30-34, Female, Negative	
HTS_TST_N_TA_OtPITC_Age_Se	31
x_Result 30-34, Female, Positive	
HTS_TST_N_TA_OtPITC_Age_Se	1,266
x_Result 30-34, Male, Negative	



HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	60
HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	724
HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	30
HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	1,095
HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	63
HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	526
HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive	47
HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	1,380
HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	141
HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	12,549
HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	298
HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	4,690
HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	91
HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	3,303
HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	54
HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	15,626
HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	381



	HTS_TST_N_TA_STI_Age_Sex_R esult 15-19, Female, Negative	75
	HTS_TST_N_TA_STI_Age_Sex_R esult 15-19, Female, Positive	1
	HTS_TST_N_TA_STI_Age_Sex_R esult 15-19, Male, Negative	250
	HTS_TST_N_TA_STI_Age_Sex_R esult 15-19, Male, Positive	1
	HTS_TST_N_TA_STI_Age_Sex_R esult 20-24, Female, Negative	75
	HTS_TST_N_TA_STI_Age_Sex_R esult 20-24, Female, Positive	1
	HTS_TST_N_TA_STI_Age_Sex_R esult 20-24, Male, Negative	250
	HTS_TST_N_TA_STI_Age_Sex_R esult 20-24, Male, Positive	1
	HTS_TST_N_TA_STI_Age_Sex_R esult 25-29, Female, Negative	50
	HTS_TST_N_TA_STI_Age_Sex_R esult 25-29, Female, Positive	1
	HTS_TST_N_TA_STI_Age_Sex_R esult 25-29, Male, Negative	93
	HTS_TST_N_TA_STI_Age_Sex_R esult 30-34, Female, Negative	43
	HTS_TST_N_TA_STI_Age_Sex_R esult 30-34, Female, Positive	2
	HTS_TST_N_TA_STI_Age_Sex_R esult 30-34, Male, Negative	72
	HTS_TST_N_TA_STI_Age_Sex_R esult 30-34, Male, Positive	5
	HTS_TST_N_TA_STI_Age_Sex_R esult 35-39, Female, Negative	24
	HTS_TST_N_TA_STI_Age_Sex_R esult 35-39, Female, Positive	1



HTS_TST_N_TA_STI_Age_Sex_R esult 35-39, Male, Negative	63
HTS_TST_N_TA_STI_Age_Sex_R esult 35-39, Male, Positive	5
HTS_TST_N_TA_STI_Age_Sex_R esult 40-49, Female, Negative	7
HTS_TST_N_TA_STI_Age_Sex_R esult 40-49, Female, Positive	2
HTS_TST_N_TA_STI_Age_Sex_R esult 40-49, Male, Negative	90
HTS_TST_N_TA_STI_Age_Sex_R esult 40-49, Male, Positive	20
HTS_TST_N_TA_STI_Age_Sex_R esult 50+, Male, Negative	4
HTS_TST_N_TA_TBC_Age_Sex_ Result 25-29, Female, Negative	14
HTS_TST_N_TA_TBC_Age_Sex_ Result 25-29, Male, Negative	18
HTS_TST_N_TA_TBC_Age_Sex_ Result 30-34, Female, Negative	8
HTS_TST_N_TA_TBC_Age_Sex_ Result 30-34, Male, Negative	14
HTS_TST_N_TA_TBC_Age_Sex_ Result 30-34, Male, Positive	1
HTS_TST_N_TA_TBC_Age_Sex_ Result 35-39, Female, Negative	3
HTS_TST_N_TA_TBC_Age_Sex_ Result 35-39, Male, Negative	9
HTS_TST_N_TA_TBC_Age_Sex_ Result 35-39, Male, Positive	1
HTS_TST_N_TA_TBC_Age_Sex_ Result 40-49, Female, Negative	4
HTS_TST_N_TA_TBC_Age_Sex_ Result 40-49, Male, Negative	17



HTS_TST_N_TA_TBC_Age_Sex_ Result 40-49, Male, Positive	2
HTS_TST_N_TA_VCT_Age_Sex_ Result 25-29, Female, Negative	4,594
HTS_TST_N_TA_VCT_Age_Sex_ Result 25-29, Female, Positive	225
HTS_TST_N_TA_VCT_Age_Sex_ Result 25-29, Male, Negative	3,821
HTS_TST_N_TA_VCT_Age_Sex_ Result 25-29, Male, Positive	85
HTS_TST_N_TA_VCT_Age_Sex_ Result 30-34, Female, Negative	4,135
HTS_TST_N_TA_VCT_Age_Sex_ Result 30-34, Female, Positive	280
HTS_TST_N_TA_VCT_Age_Sex_ Result 30-34, Male, Negative	3,274
HTS_TST_N_TA_VCT_Age_Sex_ Result 30-34, Male, Positive	251
HTS_TST_N_TA_VCT_Age_Sex_ Result 35-39, Female, Negative	3,013
HTS_TST_N_TA_VCT_Age_Sex_ Result 35-39, Female, Positive	260
HTS_TST_N_TA_VCT_Age_Sex_ Result 35-39, Male, Negative	2,799
HTS_TST_N_TA_VCT_Age_Sex_ Result 35-39, Male, Positive	267
HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Female, Negative	1,691
HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Female, Positive	345
HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Male, Negative	3,605
HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Male, Positive	531



TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	99 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	14,429
	Total number of registered new and relapsed TB cases, during the reporting period.	14,566
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	736
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7,927
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	725
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5,041
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	742





	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	7,990
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	733
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	5,101
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	97 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,115
	Total number of registered new and relapsed TB cases, during the reporting period.	1,144
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	57
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	57
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	404



	cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	643
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	55
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	625
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	55
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	395
HTS_SELF_DSD	HTS_SELF_N_DSD	231,719
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Directly-Assisted	18,418
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Unassisted	3,237
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Directly-Assisted	14,990



HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Unassisted	5,959
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Directly-Assisted	23,439
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Unassisted	4,086
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Directly-Assisted	18,709
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Unassisted	7,511
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Directly-Assisted	5,008
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Unassisted	4,113
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Directly-Assisted	37,431
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Unassisted	7,560
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Directly-Assisted	2,137
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Unassisted	2,004
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Directly-Assisted	18,867
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Unassisted	3,770



HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Directly-Assisted	2,083
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Unassisted	1,990
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Directly-Assisted	18,718
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Unassisted	3,734
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Directly-Assisted	1,677
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Unassisted	1,277
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Directly-Assisted	11,197
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Unassisted	2,254
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Female, Directly-Assisted	1,405
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Female, Unassisted	947
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Directly-Assisted	7,675
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Unassisted	1,537
HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	181,744
HTS_SELF_N_DSD_HIVSelfTest	49,975



	Unassisted	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,364,533
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,441
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	21
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	1,405
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	19
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	16,567
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	1,095
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	24,967
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	808
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	16,717
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	1,102
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	25,146
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	815
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	1,020
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	56
	Service Delivery Point (Facility)	2,467



	Inpatient: 50+, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	221
	Service Delivery Point (Facility) Inpatient: <1, Negative	815
	Service Delivery Point (Facility) Inpatient: <1, Positive	11
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	6,630
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	144
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	9
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	11
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	720
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	50
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	11,377
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	261
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	1,044
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	69



	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	11,549
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	269
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	799
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	51
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	887
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	91
	Service Delivery Point (Community) Mobile Testing: <1, Negative	3
	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	38
	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	1
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	17,638
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	415
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	17,250
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	411
	Service Delivery Point (Facility) Other PITC: 15-19, Female,	18,616



	Negative	
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	1,115
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	33,476
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	848
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	19,105
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	1,134
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	34,132
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	905
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	4,157
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	292
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	4,685
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	338
	Service Delivery Point (Facility)Other PITC: <1, Negative	9,583
	Service Delivery Point (Facility) Other PITC: <1, Positive	226
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	78,592
	Service Delivery Point (Facility) Other PITC: 1-9, Positive	1,864





	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	178
	Service Delivery Point (Community) Other: 10-14, Female, Positive	2
	Service Delivery Point (Community) Other: 10-14, Male, Negative	173
	Service Delivery Point (Community) Other: 10-14, Male, Positive	2
	Service Delivery Point (Community) Other: 15-19, Female, Negative	121
	Service Delivery Point (Community) Other: 15-19, Female, Positive	14
	Service Delivery Point (Community) Other: 15-19, Male, Negative	3,342
	Service Delivery Point (Community) Other: 15-19, Male, Positive	74
	Service Delivery Point (Community) Other: 20-24, Female, Negative	121
	Service Delivery Point (Community) Other: 20-24, Female, Positive	14
	Service Delivery Point (Community) Other: 20-24, Male, Negative	3,342
	Service Delivery Point (Community) Other: 20-24, Male, Positive	74
	Service Delivery Point (Community) Other: 50+, Male, Negative	103
	Service Delivery Point (Community) Other: 50+, Male, Positive	4
	Service Delivery Point (Community) Other: <1, Negative	102
	Service Delivery Point (Community) Other: <1, Positive	1
	Service Delivery Point (Community)	815



	Other: 1-9, Negative	
	Service Delivery Point (Community)	9
	Other: 1-9, Positive	
	Service Delivery Point (Facility)	68,485
	Pediatric : <5 Negative	
	Service Delivery Point (Facility)	806
	Pediatric : <5 Positive	
	Service Delivery Point (Facility) TB: 10-14, Female, Negative	8
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	8
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	457
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	34
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	1,173
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	27
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	458
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	34
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	1,174
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	27
	Service Delivery Point (Facility) TB: 50+, Female, Negative	6
	Service Delivery Point (Facility) TB: 50+, Male, Negative	58
	Service Delivery Point (Facility) TB: 50+, Male, Positive	11
	Service Delivery Point (Facility) TB:	5



	<1, Negative	
	Service Delivery Point (Facility) TB: 1-9, Negative	75
	Service Delivery Point (Facility) TB: 1-9, Positive	2
	Service Delivery Point (Facility) VMMC: 10-14, Negative	520
	Service Delivery Point (Facility) VMMC: 10-14, Positive	5
	Service Delivery Point (Facility) VMMC: 15-19, Negative	22,601
	Service Delivery Point (Facility) VMMC: 15-19, Positive	54
	Service Delivery Point (Facility) VMMC: 20-24, Negative	23,187
	Service Delivery Point (Facility) VMMC: 20-24, Positive	60
	Service Delivery Point (Facility) VMMC: 50+, Negative	5,150
	Service Delivery Point (Facility) VMMC: 50+, Positive	52
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	719
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	51
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	695
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	49
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	12,852
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	2,045
	Service Delivery Point (Facility)	15,055



	Index: 15-19, Male, Negative	
	Service Delivery Point (Facility)	1,993
	Index: 15-19, Male, Positive	
	Service Delivery Point (Facility)	12,897
	Index: 20-24, Female, Negative	
	Service Delivery Point (Facility)	2,060
	Index: 20-24, Female, Positive	
	Service Delivery Point (Facility)	15,108
	Index: 20-24, Male, Negative	
	Service Delivery Point (Facility)	2,010
	Index: 20-24, Male, Positive	
	Service Delivery Point (Facility)	331
	Index: 50+, Female, Negative	
	Service Delivery Point (Facility)	101
	Index: 50+, Female, Positive	
	Service Delivery Point (Facility)	3,377
	Index: 50+, Male, Negative	
	Service Delivery Point (Facility)	817
	Index: 50+, Male, Positive	
	Service Delivery Point (Facility)	408
	Index: <1, Negative	
	Service Delivery Point (Facility)	25
	Index: <1, Positive	
	Service Delivery Point (Facility)	3,318
	Index: 1-9, Negative	
	Service Delivery Point (Facility)	237
	Index: 1-9, Positive	
	By Key Population: FSW, Negative	2,482
	By Key Population: FSW, Positive	1,306
	By Key Population: MSM, Negative	832
	By Key Population: MSM, Positive	64
	By Key Population: People in prisons and other enclosed settings, Negative	746



	By Key Population: People in prisons and other enclosed settings, Positive	56
	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	78
	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	3
	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	76
	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	3
	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	949
	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	137
	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	3,686
	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	419
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	949
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	137
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	3,686
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	419
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	33
	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	5



	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	143
	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	32
	Service Delivery Point (Community) Index Mod: <1, Negative	45
	Service Delivery Point (Community) Index Mod: <1, Positive	1
	Service Delivery Point (Community) Index Mod: 1-9, Negative	356
	Service Delivery Point (Community) Index Mod: 1-9, Positive	19
	Service Delivery Point (Facility) ANC: 10-14, Negative	29,771
	Service Delivery Point (Facility) ANC: 10-14, Positive	1,008
	Service Delivery Point (Facility) ANC: 15-19, Negative	46,335
	Service Delivery Point (Facility) ANC: 15-19, Positive	1,581
	Service Delivery Point (Facility) ANC: 20-24, Negative	78,506
	Service Delivery Point (Facility) ANC: 20-24, Positive	2,699
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	8,946
	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	173
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	8,698
	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	167
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	76,846



	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	4,865
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	137,999
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	3,970
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	77,455
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	4,956
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	138,724
	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	4,059
	Service Delivery Point (Facility) VCT: 50+, Female, Negative	4,723
	Service Delivery Point (Facility) VCT: 50+, Female, Positive	225
	Service Delivery Point (Facility) VCT: 50+, Male, Negative	7,903
	Service Delivery Point (Facility) VCT: 50+, Male, Positive	662
	Service Delivery Point (Facility) VCT: <1, Negative	5,100
	Service Delivery Point (Facility) VCT: <1, Positive	99
	Service Delivery Point (Facility) VCT: 1-9, Negative	40,980
	Service Delivery Point (Facility) VCT: 1-9, Positive	801
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	862
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	87



	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	2,399
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	154
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	2,254
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	284
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	3,793
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	303
	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	97
	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	218
	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	51
	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	4,833
	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	823
	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	18,054
	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	1,480
	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	4,263
	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	952
	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	15,463
	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	3,458





HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	3,099
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	887
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	13,195
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	3,629
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	1,865
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	1,192
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	17,001
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	6,907
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	10,385
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	578
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	12,687
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	402
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	9,067
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	688
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	10,909
HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	962
HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	6,551



HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Female, Positive	633
HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Male, Negative	9,223
HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Male, Positive	991
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Negative	4,131
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Positive	863
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Negative	11,861
HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Positive	1,894
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Negative	2,027
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Positive	186
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Negative	2,725
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Positive	149
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Female, Negative	1,701
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Female, Positive	203
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Male, Negative	2,763
HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Male, Positive	315



HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	1,300
HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	189
HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	2,450
HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	327
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	1,661
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	278
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	3,631
HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	610
HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	3,095
HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	64
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	978
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	148
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	768
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	60



HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	882
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	181
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	658
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	141
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	639
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	169
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	562
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	150
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	360
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	220
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	725
HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	285
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	13,376
HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female,	708



	Positive	
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	18,117
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	559
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	11,144
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	691
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	15,848
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	1,170
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	8,423
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	655
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	13,300
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	1,173
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	7,782
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	1,023
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	17,444
	HTS_TST_N_DSD_OtPITC_Age_	2,179



	Sex_Result 40-49, Male, Positive	
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 25-29, Female, Negative	30
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 25-29, Male, Negative	550
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 25-29, Male, Positive	7
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 30-34, Female, Negative	26
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 30-34, Male, Negative	470
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 30-34, Male, Positive	20
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 35-39, Female, Negative	21
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 35-39, Male, Negative	402
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 35-39, Male, Positive	21
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 40-49, Female, Negative	10
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 40-49, Female, Positive	2
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 40-49, Male, Negative	517
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 40-49, Male, Positive	41
	HTS_TST_N_DSD_PMTCT_Age_ Sex_Result 25-29, Female,	101,583



	Negative	
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	3,364
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	29,921
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	990
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	17,644
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	623
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	130,506
	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	4,641
	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	1,017
	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	138
	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	2,868
	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	79
	HTS_TST_N_DSD_STI_Age_Sex_Result 1-9, Unknown Sex, Negative	1
	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	1,022



HTS_TST_N_DSD_STI_Age_Sex_ Result 20-24, Female, Positive	139
HTS_TST_N_DSD_STI_Age_Sex_ Result 20-24, Male, Negative	2,873
HTS_TST_N_DSD_STI_Age_Sex_ Result 20-24, Male, Positive	79
HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Female, Negative	940
HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Female, Positive	78
HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Male, Negative	1,617
HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Male, Positive	87
HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Female, Negative	841
HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Female, Positive	93
HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Male, Negative	1,379
HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Male, Positive	252
HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Female, Negative	605
HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Female, Positive	89
HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Male, Negative	1,169
HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Male, Positive	274
HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Female, Negative	335
HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Female, Positive	145





HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Male, Negative	1,518
HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Male, Positive	551
HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Female, Negative	43
HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Female, Positive	3
HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Male, Negative	283
HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Male, Positive	60
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Female, Negative	347
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Female, Positive	17
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Male, Negative	478
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Male, Positive	26
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 30-34, Female, Negative	299
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 30-34, Female, Positive	18
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 30-34, Male, Negative	412
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 30-34, Male, Positive	71
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 35-39, Female, Negative	193
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 35-39, Female, Positive	20
HTS_TST_N_DSD_TBC_Age_Sex_ _Result 35-39, Male, Negative	335



HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Male, Positive	75
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Negative	251
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Positive	29
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Negative	456
HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Positive	155
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Negative	56,555
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Positive	2,808
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Negative	39,914
HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Positive	1,191
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Negative	49,729
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Positive	3,359
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Negative	34,380
HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Positive	2,752
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Negative	36,009
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Positive	3,163
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Negative	28,944
HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Positive	2,874



HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Negative	22,040
HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Positive	4,082
HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Negative	37,179
HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Positive	5,389
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Female, Negative	3,450
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Female, Positive	510
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Male, Negative	3,193
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Male, Positive	341
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Female, Negative	1,510
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Female, Positive	582
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Male, Negative	1,438
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Male, Positive	440
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 35-39, Female, Negative	492
HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 35-39, Female, Positive	117



	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	1,004
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	286
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	103
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	39
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	898
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	472
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	26,156
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	100
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	22,676
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	211
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	19,164
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	218
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	24,464
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	405
GEND_GBVDSD	Number of people receiving post-GBV care	4,618
	By type of service: Physical and/or Emotional Violence (Other	2,449



	Post-GBV Care)	
	By type of service: Sexual Violence (Post-Rape Care)	2,167
	By PEP service provision (related to sexual violence services provided)	2,168
	<10, Female, Sexual Violence (Post-Rape Care)	845
	10-14, Female, Physical and/or Emotional Violence	312
	10-14, Female, Sexual Violence (Post-Rape Care)	348
	15-19, Female, Physical and/or Emotional Violence	530
	15-19, Female, Sexual Violence (Post-Rape Care)	408
	15-19, Male, Physical and/or Emotional Violence	32
	15-19, Male, Sexual Violence (Post-Rape Care)	3
	20-24, Female, Physical and/or Emotional Violence	875
	20-24, Female, Sexual Violence (Post-Rape Care)	459
	20-24, Male, Physical and/or Emotional Violence	87
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	432
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	100
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male,	68



	Physical and/or Emotional Violence	
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	62
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	7
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	5
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	39
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	6
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	126,564
	Age/Sex: 10-14 Male	12,484
	Age/Sex: 15-17 Male	9,789
	By: Age/sex: Male 18-24	3,883
	By: Age/sex: Male 25+	7,109
	Age/Sex: 10-14 Female	22,378
	Age/Sex: 15-17 Female	21,343
	By: Age/sex: 18-24 Female	20,905
	By: Age/sex: 25+ Female	19,015
	Sum of Age/Sex disaggregates	65,994
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	9,236
	Required only for DREAMS	2,977



	countries - By service, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	2
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	356
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	311
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	1,200
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	2,625
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	1,978
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	1,236
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	2,392
	Required only for DREAMS countries - By service, age and	1,888



	sex: Parenting/Caregiver Programs Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	425
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	205
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	196
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	428
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	197
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	188
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	2,879
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	3,326
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	3,475





	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	2,850
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	3,015
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	3,278
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	1,558
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	771
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	719
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	1,589
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	725
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	635
	Age/Sex: <1	598
	Age/Sex: 1-9	9,084
	Program Completion: Active	88,059
	Program Completion: Graduation	38,505
OVC_HIVSTAT_DSD	OVC_HIVSTAT_DSD Number of	57 %



	orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	
	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	71,842
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	126,564
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	7,153
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	338
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,944
	Aggregated Age/Sex: Female <15	361



	(Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,516
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	757
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	40
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	414



	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	41
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	267
TB_PREV_DSD	TB_PREV_DSD TB_PREV_DSD	89 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	226,456
	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	255,466
	By Age/Sex (Denominator): <15, Female	12,764
	By Age/Sex (Denominator): <15, Male	12,765
	By Age/Sex (Denominator): 15+,	89,383



	Female	
	By Age/Sex (Denominator): 15+, Male	140,469
	By Age/Sex (Numerator): <15, Female	11,312
	By Age/Sex (Numerator): <15, Male	11,312
	By Age/Sex (Numerator): 15+, Female	79,257
	By Age/Sex (Numerator): 15+, Male	124,575
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	25,515
	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	229,866
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	22,650
	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	203,806
TB_PREV_TA	TB_PREV_TA TB_PREV_TA	90 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	10,148
	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting	11,276



	period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
	By Age/Sex (Denominator): <15, Female	562
	By Age/Sex (Denominator): <15, Male	562
	By Age/Sex (Denominator): 15+, Female	3,950
	By Age/Sex (Denominator): 15+, Male	6,202
	By Age/Sex (Numerator): <15, Female	508
	By Age/Sex (Numerator): <15, Male	508
	By Age/Sex (Numerator): 15+, Female	3,555
	By Age/Sex (Numerator): 15+, Male	5,577
	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	1,126
	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	10,150
	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	1,016
	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	9,132
TX_TB_DSD	TX_TB_DSD The proportion of ART patients who were screened	0 %



	who are receiving TB treatment	
	Number of ART patients who were screened for TB at least once during the reporting period	891,713
	Denominator: By Aggregated Age/Sex: <15, Female	44,447
	Denominator: By Aggregated Age/Sex: <15, Male	45,883
	Denominator: By Aggregated Age/Sex:15+, Female	309,844
	Denominator: By Aggregated Age/Sex:15+, Male	491,539
	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	891,711
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	364,464
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	527,247
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	791,735
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	8,884
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	90,243
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New,	851



	TB Screen - Positive, Positive	
TX_TB_TA	TX_TB_TA The proportion of ART patients who were screened who are receiving TB treatment	0 %
	Number of ART patients who were screened for TB at least once during the reporting period	84,108
	Denominator: By Aggregated Age/Sex: <15, Female	4,195
	Denominator: By Aggregated Age/Sex: <15, Male	4,195
	Denominator: By Aggregated Age/Sex: 15+, Female	29,434
	Denominator: By Aggregated Age/Sex: 15+, Male	46,284
	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	84,108
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	0
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	33,642
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	50,466
	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	74,913
	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive,	828



	Positive	
	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	8,328
	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	80
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	37,538
	By infants who received a virologic test within 2 months of birth	29,964
	By infants who received their first virologic HIV test between 2 and 12 months of age	7,574
	Sum of Infant Age disaggregates	37,538
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,897
	By infants who received a virologic test within 2 months of birth	2,322
	By infants who received their first virologic HIV test between 2 and 12 months of age	575
	Sum of Infant Age disaggregates	2,897
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy	890,225



	(ART)	
	Age/Sex: 15-19 Male	13,833
	Age/Sex: 15-19 Female	14,105
	Age/Sex: <1	3,713
	Age/Sex: <1-9	33,821
	Age/Sex: 10-14 Male	16,087
	Age/Sex: 10-14 Female	17,215
	Age/Sex: 20-24 Male	13,160
	Age/Sex: 50+ Male	74,513
	Age/Sex: 20-24 Female	35,861
	Age/Sex: 50+ Female	71,621
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Female, Positive	60,436
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Male, Positive	14,556
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Female, Positive	93,033
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Male, Positive	32,253
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Female, Positive	103,799
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive	53,193
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive	132,287
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive	106,825
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	82,897
	Age/Sex: 15-19 Male	1,278
	Age/Sex: 15-19 Female	1,308
	Sum of Age/Sex disaggregations	2,586



	Age/Sex: <1	385
	Age/Sex: 1-9	3,521
	Age/Sex: 10-14 Male	1,665
	Age/Sex: 10-14 Female	1,794
	Age/Sex: 20-24 Male	1,172
	Age/Sex: 50+ Male	7,211
	Age/Sex: 20-24 Female	3,277
	Age/Sex: 50+ Female	6,898
	TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Female, Positive	5,407
	TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Male, Positive	1,285
	TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Female, Positive	8,370
	TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Male, Positive	2,852
	TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Female, Positive	9,474
	TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive	4,682
	TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Female, Positive	12,590
	TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive	9,728
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	125,535
	By Age/Sex: <1	1,244
	By Age/Sex: 1-9	3,760
	By Age/Sex: 10-14 Male	528
	By Age/Sex: 15-19 Male	8,235
	By Age/Sex: 20-24 Male	8,362
	By Age/Sex: 50+ Male	2,276



	By Age/Sex: 10-14 Female	542
	By Age/Sex: 15-19 Female	10,440
	By Age/Sex: 20-24 Female	13,097
	By Age/Sex: 50+ Female	230
	Pregnancy status	26,057
	Breastfeeding status	7,013
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Female, Positive	7,066
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Male, Positive	4,198
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Female, Positive	8,545
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Male, Positive	9,739
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Female, Positive	7,970
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Male, Positive	10,124
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Female, Positive	9,914
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Male, Positive	19,250
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	10,447
	By Age/Sex: <1	74
	By Age/Sex: 1-9	258
	By Age/Sex: 10-14 Male	20
	By Age/Sex: 15-19 Male	765
	By Age/Sex: 20-24 Male	765
	By Age/Sex: 50+ Male	154
	By Age/Sex: 10-14 Female	23
	By Age/Sex: 15-19 Female	984



	By Age/Sex: 20-24 Female	1,204
	By Age/Sex: 50+ Female	2
	Sum of Age/Sex disaggregates	3,917
	Pregnancy status	2,155
	Breastfeeding status	568
	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	580
	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	290
	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	700
	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	713
	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	681
	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	758
	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	1,016
	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	1,460
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	570,839
	<15, Undocumented Test	3



	Indication, Female	
	<15, Undocumented Test Indication, Male	3
	15+, Undocumented Test Indication, Female	10
	15+, Undocumented Test Indication, Male	6
	Undocumented Test Indication	22
	Denominator: Indication: Routine	553,886
	Denominator: Indication: Targeted	16,931
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	2,814
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	5,633
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	2,815
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	5,652
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	19,565
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	191,805
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	20,438
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	322,095
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
	Number of adult and pediatric ART	50,523



	patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	
	Denominator: Indication: Routine	49,009
	Denominator: Indication: Targeted	1,514
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,807
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	251
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,725
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	251
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	28,614
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	508
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	16,859
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	508
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	99 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	158,165
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to	159,706



	follow-up	
	Numerator by Status: Pregnant	4,323
	Numerator by Status: Breastfeeding	5,165
	Denominator by Status: Pregnant	4,596
	Denominator by Status: Breastfeeding	6,248
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,102
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	78,542
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,133
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	67,565
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,329





	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	79,127
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,361
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	68,068
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	99 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	12,707
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	12,823



	stopped ART, and those lost to follow-up	
	Numerator by Status: Pregnant	202
	Numerator by Status: Breastfeeding	388
	Denominator by Status: Pregnant	203
	Denominator by Status: Breastfeeding	390
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	676
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,154
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	679
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,198
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	712



	those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,192
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	715
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,204



## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
10427	Malawi Blood Transfusion Service	Parastatal	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	580,000
11453	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	8,000
12116	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	200,000
12131	Christian Health Association of Malawi	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	770,016
14441	Lighthouse	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,917,063
14442	BAOBAB Health Partnership	NGO	U.S. Department of Health and	GHP-State	3,323,989



			Human Services/Centers for Disease Control and Prevention		
15888	UNICEF	Multi-lateral Agency	U.S. Agency for International Development	GHP-State, GHP-USAID	635,227
16486	Save The Children Federation Inc	NGO	U.S. Agency for International Development		
16704	Johns Hopkins University Center for Communication Programs	University	U.S. Agency for International Development	GHP-State	11,698,069
16716	Counterpart International	NGO	U.S. Agency for International Development		
17097	Project Concern International	NGO	U.S. Department of Defense	GHP-State	1,850,000
17268	Columbia University	University	U.S. Department of Health and Human Services/Health Resources and Services Administration		
17341	University Research Corporation, LLC	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,671,540



17451	Universtiy of Washington	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,652,578
17480	Palladium Group	NGO	U.S. Agency for International Development	GHP-State	530,000
17487	National Registration Bureau Malawi	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	450,000
17488	University of Malawi College of Medicine	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	721,547
17585	FHI 360	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	3,760,663
17590	Population Council	NGO	U.S. Agency for International Development	GHP-State	500,000
18005	KNCV Tuberculosis Foundation	NGO	U.S. Agency for International Development	GHP-State	1,640,000
18024	University of Washington	University	U.S. Department of Health and Human	GHP-State	3,410,000



			Services/Centers for Disease Control and Prevention		
18025	Lighthouse	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,295,974
18028	World Learning	NGO	U.S. Agency for International Development	GHP-State	790,000
18045	JHPIEGO	University	U.S. Department of Defense	GHP-State	439,176
18063	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	4,006,740
18142	Population Services International	NGO	U.S. Agency for International Development		
18234	Right To Care, South Africa	NGO	U.S. Agency for International Development	GHP-USAID	4,163,723
18244	JHPIEGO	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,476,430
18245	Christian Health Association of Malawi	FBO	U.S. Department of Health and Human	GHP-State	1,700,000



			Services/Centers for Disease Control and Prevention		
18246	Health Research Inc./New York State Department of Health	Other USG Agency	U.S. Department of Health and Human Services/Health Resources and Services Administration		
18247	JHPIEGO	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,350,000
18256	Regional Procurement Support Office/Frankfurt	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	542,825
18279	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	920,192
18303	FHI 360	NGO	U.S. Agency for International Development		
18305	Chemonics International	Private Contractor	U.S. Agency for International Development	GHP-State	1,652,000
18351	TBD	TBD	Redacted	Redacted	Redacted
18479	Marie Stopes International	NGO	U.S. Agency for International Development		





18544	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	15,310,368
18548	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
18603	Pact	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	553,543
18649	TBD	TBD	Redacted	Redacted	Redacted
18654	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	3,652,656
70175	TBD	TBD	Redacted	Redacted	Redacted
70185	Baylor College of Medicine Children's Foundation	University	U.S. Agency for International Development	GHP-State, GHP-USAID	10,502,164
70186	TBD	TBD	Redacted	Redacted	Redacted
70188	TBD	TBD	Redacted	Redacted	Redacted
70189	TBD	TBD	Redacted	Redacted	Redacted
70190	TBD	TBD	Redacted	Redacted	Redacted
70191	TBD	TBD	Redacted	Redacted	Redacted
80043	Remote Medical International	Private Contractor	U.S. Agency for International Development	GHP-State	157,500



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 10427</b>	<b>Mechanism Name: Supporting the Safe, Adequate and Reliable Supply of Blood and Blood Products through the Malawi Blood Transfusion Service and its Support to Hospitals throughout Malawi, under the PEPFAR and the Global Health Initiative</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Malawi Blood Transfusion Service	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 580,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 580,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	580,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	10427
<b>Mechanism Name:</b>	Supporting the Safe, Adequate and Reliable Supply of Blood and Blood Products through the Malawi Blood Transfusion Service and its Support to Hospitals throughout Malawi, under
<b>Prime Partner Name:</b>	



<b>the PEPFAR and the Global Health Initiative Malawi Blood Transfusion Service</b>		
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	580,000

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 11453</b>		<b>Mechanism Name: Peace Corps Volunteers</b>	
Funding Agency: PC		Procurement Type: USG Core	
Prime Partner Name: U.S. Peace Corps			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: N/A			
G2G: No		Managing Agency:	

<b>Total All Funding Sources: 8,000</b>		<b>Total Mechanism Pipeline: N/A</b>	
<b>Applied Pipeline Amount: 158,560</b>			
<b>Total All Funding Sources and Applied Pipeline Amount: 166,560</b>			
<b>Funding Source</b>		<b>Funding Amount</b>	
GHP-State		8,000	

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 11453</b>
----------------------------



<b>Mechanism Name: Peace Corps Volunteers</b>		
<b>Prime Partner Name: U.S. Peace Corps</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	7,500
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	500
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	8,154
PP_PREV_DSD	Age/sex: 10-14 Male	571
PP_PREV_DSD	Age/sex: 15-19 Male	1,628
PP_PREV_DSD	Age/sex: 20-24 Male	818
PP_PREV_DSD	Age/sex: 50+ Male	1
PP_PREV_DSD	Age/sex: 10-14 Female	1,057



PP_PREV_DSD	Age/sex: 15-19 Female	2,440
PP_PREV_DSD	Age/sex: 20-24 Female	407
PP_PREV_DSD	Age/sex: 50+ Female	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	6,922
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	326
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	168
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	245
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	168
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	80
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	80
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	81
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	81
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0
PP_PREV_TA	Age/sex: 10-14 Male	0
PP_PREV_TA	Age/sex: 15-19 Male	0
PP_PREV_TA	Age/sex: 20-24 Male	0
PP_PREV_TA	Age/sex: 50+ Male	0
PP_PREV_TA	Age/sex: 10-14 Female	0
PP_PREV_TA	Age/sex: 15-19 Female	0
PP_PREV_TA	Age/sex: 20-24 Female	0
PP_PREV_TA	Age/sex: 50+ Female	0
PP_PREV_TA	Sum of Age/Sex disaggregates	0
PP_PREV_TA	PP_PREV_N_TA_Age_Sex_v2 25-29, Female	0
PP_PREV_TA	PP_PREV_N_TA_Age_Sex_v2 25-29, Male	0
PP_PREV_TA	PP_PREV_N_TA_Age_Sex_v2 30-34, Female	0
PP_PREV_TA	PP_PREV_N_TA_Age_Sex_v2 30-34, Male	0
PP_PREV_TA	PP_PREV_N_TA_Age_Sex_v2 35-39, Female	0
PP_PREV_TA	PP_PREV_N_TA_Age_Sex_v2 35-39, Male	0
PP_PREV_TA	PP_PREV_N_TA_Age_Sex_v2 40-49, Female	0
PP_PREV_TA	PP_PREV_N_TA_Age_Sex_v2 40-49, Male	0



OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	330
OVC_SERV_DSD	Age/Sex: 10-14 Male	13
OVC_SERV_DSD	Age/Sex: 15-17 Male	118
OVC_SERV_DSD	By: Age/sex: Male 18-24	68
OVC_SERV_DSD	By: Age/sex: Male 25+	4
OVC_SERV_DSD	Age/Sex: 10-14 Female	30
OVC_SERV_DSD	Age/Sex: 15-17 Female	56
OVC_SERV_DSD	By: Age/sex: 18-24 Female	33
OVC_SERV_DSD	By: Age/sex: 25+ Female	49
OVC_SERV_DSD	Sum of Age/Sex disaggregates	217
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	6
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	18
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	2
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	3
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	8
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	24
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	10
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	4
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	15



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	5
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	2
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	7
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	1
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	3
OVC_SERV_DSD	Program Completion: Active	330

**Implementing Mechanism Details**

<b>Mechanism ID: 12116</b>	<b>Mechanism Name: ASGF/State for Ambassadors Small Grant for HIV/AIDS</b>
Funding Agency: State/AF	Procurement Type: Cooperative Agreement
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 200,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 200,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	200,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)





**Budget Code Information**

<b>Mechanism ID:</b> 12116		
<b>Mechanism Name:</b> ASGF/State for Ambassadors Small Grant for HIV/AIDS		
<b>Prime Partner Name:</b> U.S. Department of State		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	100,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	100,000

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 12131</b>	<b>Mechanism Name: Strengthening the Delivery, Coordination, and Monitoring of HIV Services in Malawi through a Faith-based Institution under the President's Emergency Plan for AIDS Relief (PEPFAR)</b>	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Christian Health Association of Malawi		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	
<b>Total All Funding Sources: 770,016</b>	<b>Total Mechanism Pipeline: N/A</b>	
<b>Applied Pipeline Amount: 0</b>		
<b>Total All Funding Sources and Applied Pipeline Amount: 770,016</b>		

Approved



Funding Source	Funding Amount
GHP-State	770,016

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	404,000
----------------------------	---------

**Budget Code Information**

<b>Mechanism ID:</b>	12131	
<b>Mechanism Name:</b>	Strengthening the Delivery, Coordination, and Monitoring of HIV Services in Malawi through a Faith-based Institution under the	
<b>Prime Partner Name:</b>	President's Emergency Plan for AIDS Relief (PEPFAR) Christian Health Association of Malawi	
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	167,509
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	502,507
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	90,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	10,000

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**



<b>Mechanism ID: 14441</b>	<b>Mechanism Name: Center of Excellence for Comprehensive Integrated HIV Care and Treatment Services in Lilongwe, Malawi</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Lighthouse	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,917,063</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,917,063</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,917,063

### Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	195,696
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	34,534
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Motor Vehicles: Purchased	90,000
Human Resources for Health	2,145,356

### Budget Code Information



<b>Mechanism ID:</b>	14441	
<b>Mechanism Name:</b>	Center of Excellence for Comprehensive Integrated HIV Care and Treatment Services in Lilongwe, Malawi	
<b>Prime Partner Name:</b>	Lighthouse	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	48,449
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	739,234
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	107,011
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	55,025
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	553,783
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	150,025
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	415,025
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	2,528,742
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	319,769



## Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,770
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	40,248
PMTCT_ART_DSD	New on ART	1,193
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,577
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	40,248
PMTCT_STAT_DSD	Number of new ANC and L&D clients	43,242
PMTCT_STAT_DSD	By Age (Denominator): 10-14	99
PMTCT_STAT_DSD	By Age (Denominator): <15-19	9,753
PMTCT_STAT_DSD	By Age (Denominator): 20-24	15,215
PMTCT_STAT_DSD	By Age (Denominator): 50+	34
PMTCT_STAT_DSD	By Number of known positives: 10-14	3
PMTCT_STAT_DSD	By Number of known positives: 15-19	372
PMTCT_STAT_DSD	By Number of known positives: 20-24	580
PMTCT_STAT_DSD	By Number of new positives: 10-14	1
PMTCT_STAT_DSD	By Number of new positives: 15-19	287
PMTCT_STAT_DSD	By Number of new positives: 20-24	448
PMTCT_STAT_DSD	By Number of new negative: 10-14	86
PMTCT_STAT_DSD	By Number of new negative: 15-19	8,419
PMTCT_STAT_DSD	By Number of new negative: 20-24	13,133
PMTCT_STAT_DSD	By Number of new negative: 50+	29
PMTCT_STAT_DSD	By Age (Numerator): 10-14	94
PMTCT_STAT_DSD	By Age (Numerator): 15-19	9,078



PMTCT_STAT_DSD	By Age (Numerator): 20-24	14,161
PMTCT_STAT_DSD	By Age (Numerator): 50+	32
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	14,774
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	2,728
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	558
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	81
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	562
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	12,753
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	435
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	105
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	2,353
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	80
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	20
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	483
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	15
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	1
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	70
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	1
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	13,747
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	2,536
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	520



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	77
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	196,369
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	117
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	114
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	353
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	4,170
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	162
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	353
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	4,170
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	162
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	212
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	26



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	67
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	536
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,124
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	1,091
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	560
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	6,662
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	166
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	560
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	6,662
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	166
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	335
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	27





HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	647
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	5,163
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	169
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	7,269
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	114
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	250
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	250
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	1



HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	58
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	55
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	308
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	2,474
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	363
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	308
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	2,474
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	363
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	282
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	81
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	263
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	22



HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	5,292
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	152
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	6,616
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	190
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	7,497
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	215
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	1,021
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	990
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	2,032
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	169
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	24,310
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	894
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	2,032
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	169
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	24,310
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	894
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	1



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	785
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	93
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	588
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	4,683
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	81
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	1,518
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	142
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	1,299
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	339
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	1,111
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	358
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	7



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	1,432
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	682
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	47
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	1,140
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	48
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	976
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	112
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	30
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	835
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	118
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	6



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	1,077
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	226
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	74
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	1,800
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	48
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	66
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	1,541
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	114
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	48
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	1,317
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	120
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	27
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	1,698



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	229
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	8,821
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	254
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	15,877
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	456
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	512
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	19
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	512
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	163
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	3



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	139
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	119
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	154
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	30
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	66
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	1





HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	56
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	48
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	63
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	329
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	4,222
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	166
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	296
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	3,612
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	396
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	216

HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	3,089
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	417
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	121
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	3,982
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	797
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,523
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,531
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	76
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	838
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	76
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	533
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	76
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total	843



	number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	76
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	536
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	726
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	35
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	401
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	36
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	254
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,770
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,216
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	554
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,770
TX_CURR_DSD	Number of adults and children receiving antiretroviral	58,656



	therapy (ART)	
TX_CURR_DSD	Age/Sex: 15-19 Male	740
TX_CURR_DSD	Age/Sex: 15-19 Female	644
TX_CURR_DSD	Sum of age/sex disaggregates	1,384
TX_CURR_DSD	Age/Sex: <1	295
TX_CURR_DSD	Age/Sex: <1-9	2,656
TX_CURR_DSD	Age/Sex: 10-14 Male	1,210
TX_CURR_DSD	Age/Sex: 10-14 Female	1,274
TX_CURR_DSD	Age/Sex: 20-24 Male	969
TX_CURR_DSD	Age/Sex: 50+ Male	4,234
TX_CURR_DSD	Age/Sex: 20-24 Female	2,367
TX_CURR_DSD	Age/Sex: 50+ Female	4,045
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	4,439
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	967
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	6,629
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,146
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	6,906
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	3,644
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	8,684
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	6,807
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	9,937
TX_NEW_DSD	By Age/Sex: <1	112
TX_NEW_DSD	By Age/Sex: 1-9	362
TX_NEW_DSD	By Age/Sex: 10-14 Male	51



TX_NEW_DSD	By Age/Sex: 15-19 Male	1,429
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,429
TX_NEW_DSD	By Age/Sex: 50+ Male	239
TX_NEW_DSD	By Age/Sex: 10-14 Female	53
TX_NEW_DSD	By Age/Sex: 15-19 Female	328
TX_NEW_DSD	By Age/Sex: 20-24 Female	542
TX_NEW_DSD	By Age/Sex: 50+ Female	1
TX_NEW_DSD	Sum of Age/Sex disaggregates	4,072
TX_NEW_DSD	Pregnancy status	1,994
TX_NEW_DSD	Breastfeeding status	534
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	176
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	423
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	214
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	1,011
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	208
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	1,065
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	262
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	2,032
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	40,180
TX_PVLS_DSD	Denominator: Indication: Routine	38,976
TX_PVLS_DSD	Denominator: Indication: Targeted	1,204
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	201



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	402
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	201
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	402
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,326
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	13,197
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,365
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	23,086
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	8,278
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	8,355
TX_RET_DSD	Numerator by Status: Pregnant	136
TX_RET_DSD	Numerator by Status: Breastfeeding	250
TX_RET_DSD	Denominator by Status: Pregnant	137
TX_RET_DSD	Denominator by Status: Breastfeeding	424
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	364
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,152
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	366
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number	1,396



	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	378
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,192
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	380
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,405
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	36,544
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	40,600
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	2,029
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	2,030



TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	14,210
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	22,331
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	1,827
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	1,827
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	12,790
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	20,100
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	4,056
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	36,544
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	3,655
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	32,889
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	68,572
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	3,407
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	3,407
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	24,022
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	37,736
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	68,572
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	27,479
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	41,093
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	61,026
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	685
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	6,835





TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	26
-----------	---	----

**Implementing Mechanism Details**

<b>Mechanism ID: 14442</b>	<b>Mechanism Name: Improving Quality of Care and Health Impact through Sustainable, Integrated, Innovative Information System Technologies in Malawi under PEPFAR</b>	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: BAOBAB Health Partnership		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

<b>Total All Funding Sources: 3,323,989</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,323,989</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,323,989

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	14442	
<b>Mechanism Name:</b>	Improving Quality of Care and Health Impact through Sustainable, Integrated, Innovative Information System Technologies in Malawi under PEPFAR	
<b>Prime Partner Name:</b>	BAOBAB Health Partnership	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	104,884
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	111,392
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	2,976
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	116,051
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	29,755
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	104,883
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	1,149,851
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	1,341,080
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	363,117

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**



<b>Mechanism ID: 15888</b>	<b>Mechanism Name: Strengthening the National OVC Program</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: UNICEF	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 530,520</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 530,520</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-USAID	530,520

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	22,066
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Human Resources for Health	150,000

**Budget Code Information**

<b>Mechanism ID:</b>	15888	
<b>Mechanism Name:</b>	Strengthening the National OVC Program	
<b>Prime Partner Name:</b>	UNICEF	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0



Strategic Area	Budget Code	Planned Amount
Care	HKID	635,227
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16486</b>	<b>Mechanism Name: ASPIRE</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Save The Children Federation Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 16486 <b>Mechanism Name:</b> ASPIRE <b>Prime Partner Name:</b> Save The Children Federation Inc		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

**Implementing Mechanism Indicator Information**



(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 16704</b>	<b>Mechanism Name: One Community (One C)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Johns Hopkins University Center for Communication Programs	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 11,698,069</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 11,698,069</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	11,698,069

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	448,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Sub Area:	Implementation
Motor Vehicles: Purchased	282,558
Economic Strengthening	100,000
Education	300,000
Adolescent Girls and Young Women (AGYW)	3,545,219





**Budget Code Information**

<b>Mechanism ID: 16704</b>		
<b>Mechanism Name: One Community (One C)</b>		
<b>Prime Partner Name: Johns Hopkins University Center for Communication Programs</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	885,458
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	4,473,441
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	1,499,320
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	2,165,713
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	433,722
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	261,646
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	1,978,769
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	239,442
PP_PREV_DSD	Age/sex: 10-14 Male	7,083



PP_PREV_DSD	Age/sex: 15-19 Male	5,937
PP_PREV_DSD	Age/sex: 20-24 Male	8,647
PP_PREV_DSD	Age/sex: 10-14 Female	23,785
PP_PREV_DSD	Age/sex: 15-19 Female	52,179
PP_PREV_DSD	Age/sex: 20-24 Female	56,434
PP_PREV_DSD	Sum of Age/Sex disaggregates	154,065
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	6,737
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	13,380
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	6,872
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	15,410
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	7,059
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	15,221
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	6,567
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	14,131
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	45,443
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	230
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	3,851
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	76
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	326
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	3,976
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	83



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	576
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	38
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	432
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	178
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Male, Negative	173
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	101
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	2,036
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	42
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	101
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	2,036
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	42
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	75



HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Other: <1, Negative	102
HTC_TST_DSD	Service Delivery Point (Community) Other: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Negative	815
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	42
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	39
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	651
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	96
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	579
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	69
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	651
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	96
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	579
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	69
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	2



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	174
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	189
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	35
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	34
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	743
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	107
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	2,218
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	237
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	743
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	107
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	2,218
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	237
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+,	28



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	87
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	21
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	160
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	42
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	42
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	9
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	240
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	939
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	69
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34,	213



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	801
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	168
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	156
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	687
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	177
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	885
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	339
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	959
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	89
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	1,032
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	766
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	95





	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	972
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	99
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	570
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	89
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	832
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	101
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	817
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	140
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	1,163
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	183
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	802
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	120
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	465
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	35
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	723
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	146
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	399



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	83
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	525
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	138
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	340
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	88
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	296
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	177
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	439
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	167
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	26
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	400
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	342
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	18
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	293



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	376
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	48
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	41
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	35
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	46
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	18



	Male, Positive	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	112,332
OVC_SERV_DSD	Age/Sex: 10-14 Male	10,830
OVC_SERV_DSD	Age/Sex: 15-17 Male	8,139
OVC_SERV_DSD	By: Age/sex: Male 18-24	3,519
OVC_SERV_DSD	By: Age/sex: Male 25+	6,631
OVC_SERV_DSD	Age/Sex: 10-14 Female	19,066
OVC_SERV_DSD	Age/Sex: 15-17 Female	18,224
OVC_SERV_DSD	By: Age/sex: 18-24 Female	20,487
OVC_SERV_DSD	By: Age/sex: 25+ Female	17,160
OVC_SERV_DSD	Sum of Age/Sex disaggregates	56,259
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	9,230
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	2,959
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	353
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	303
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	1,200
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	2,625
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	1,954
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	1,236
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	2,392
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	1,878



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	424
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	201
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	196
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	428
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	196
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	188
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	2,879
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	3,326
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	3,460
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	2,850
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	3,015
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	3,273
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	1,556
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	764
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	718
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	1,588
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	722



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	635
OVC_SERV_DSD	Age/Sex: <1	598
OVC_SERV_DSD	Age/Sex: 1-9	7,662
OVC_SERV_DSD	Program Completion: Active	80,798
OVC_SERV_DSD	Program Completion: Graduation	31,534
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	61,419
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	112,332
HTS_SELF_DSD	HTS_SELF_N_DSD	10,699
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	860
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	150
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	703
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	280
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	1,091
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	190
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	871
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	351
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	217
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	190
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	1,744



	Male, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	351
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	97
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	93
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	870
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	173
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	97
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	93
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	870
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	173
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	60
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	56
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	514
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	102
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	40
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	354
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male,	70



	Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	8,388
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	2,311

**Implementing Mechanism Details**

<b>Mechanism ID: 16716</b>		<b>Mechanism Name: STEPS</b>	
Funding Agency: USAID		Procurement Type: Cooperative Agreement	
Prime Partner Name: Counterpart International			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: N/A			
G2G: No		Managing Agency:	

<b>Total All Funding Sources: 0</b>		<b>Total Mechanism Pipeline: N/A</b>	
<b>Applied Pipeline Amount: 0</b>			
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>			
<b>Funding Source</b>		<b>Funding Amount</b>	

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 16716</b>		
<b>Mechanism Name: STEPS</b>		
<b>Prime Partner Name: Counterpart International</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>





Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17097</b>	<b>Mechanism Name: DOD Support to Malawi Defense Force HIV AIDS Program</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Project Concern International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,850,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,850,000</b>	
Funding Source	Funding Amount



GHP-State	1,850,000
-----------	-----------

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	20,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Adolescent Girls and Young Women (AGYW)	200,000

**Budget Code Information**

<b>Mechanism ID:</b> 17097 <b>Mechanism Name:</b> DOD Support to Malawi Defense Force HIV AIDS Program <b>Prime Partner Name:</b> Project Concern International		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	139,500
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	46,500
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	45,000
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	60,000
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	232,500
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	150,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	45,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	899,000
Strategic Area	Budget Code	Planned Amount



Treatment	PDTX	232,500
-----------	------	---------

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	108
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,144
PMTCT_ART_DSD	New on ART	25
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	83
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,144
PMTCT_STAT_DSD	Number of new ANC and L&D clients	1,144
PMTCT_STAT_DSD	By Age (Denominator): 10-14	3
PMTCT_STAT_DSD	By Age (Denominator): <15-19	242
PMTCT_STAT_DSD	By Age (Denominator): 20-24	383
PMTCT_STAT_DSD	By Age (Denominator): 50+	1
PMTCT_STAT_DSD	By Number of known positives: 15-19	18
PMTCT_STAT_DSD	By Number of known positives: 20-24	28
PMTCT_STAT_DSD	By Number of new positives: 15-19	5
PMTCT_STAT_DSD	By Number of new positives: 20-24	9
PMTCT_STAT_DSD	By Number of new negative: 10-14	3
PMTCT_STAT_DSD	By Number of new negative: 15-19	218
PMTCT_STAT_DSD	By Number of new negative: 20-24	346
PMTCT_STAT_DSD	By Number of new negative: 50+	1
PMTCT_STAT_DSD	By Age (Numerator): 10-14	3
PMTCT_STAT_DSD	By Age (Numerator): 15-19	242
PMTCT_STAT_DSD	By Age (Numerator): 20-24	383

PMTCT_STAT_DSD	By Age (Numerator): 50+	1
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	269
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	157
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	73
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	16
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	20
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	244
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	6
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	11
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	142
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	4
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	5
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	66
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	2
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	1
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	15
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	269
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	157
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	73
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	16
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	4,153



PP_PREV_DSD	Age/sex: 10-14 Male	165
PP_PREV_DSD	Age/sex: 15-19 Male	331
PP_PREV_DSD	Age/sex: 20-24 Male	456
PP_PREV_DSD	Age/sex: 50+ Male	166
PP_PREV_DSD	Age/sex: 10-14 Female	208
PP_PREV_DSD	Age/sex: 15-19 Female	415
PP_PREV_DSD	Age/sex: 20-24 Female	623
PP_PREV_DSD	Age/sex: 50+ Female	125
PP_PREV_DSD	Sum of Age/Sex disaggregates	2,489
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	208
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	208
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	208
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	208
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	208
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	208
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	208
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	208
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	43,030
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	41
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	184
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male,	68



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	334
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	247
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	705
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	211
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	146
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	11
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	48
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	18
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	1





HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	87
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	65
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	184
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	55
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Negative	3
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	38
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	61
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	72
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	326
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	42



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	121
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	591
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	76
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	437
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1,249
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	160
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	373
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	259
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	1



HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	350
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	150
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	550
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	500
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	54
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	99
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	73



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	209
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	70
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	62
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	64
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	84
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	142
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	140
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	166
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	747
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	278
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	1,356



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1,003
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	2,866
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	93
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	855
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	46
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	595
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	137
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	46
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	142
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	35
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	139
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	46



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	15
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	85
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	141
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	47
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	100
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	462
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	480
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	118
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	469
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	51



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	289
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	478
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	337
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	121
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	125
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	31
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	123
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	75



HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	125
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	88
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	818
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	105
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	849
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	109
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	208
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	831
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	107
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	91
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	511
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	66





HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	846
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	108
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	596
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	76
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	200
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	123
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	92
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	329
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 1-9, Unknown Sex, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	1



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	21
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	6



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	1,877
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	61
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	1,949
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	63
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	478
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	1,907
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	209
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	7

HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	1,173
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	38
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	1,941
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	63
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	1,367
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	44
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	1,001
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	1,051
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	650
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	750
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	7
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	55
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	55
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with	3



	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	30
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	19
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	30
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	19
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	28
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	24
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	109



PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	27
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	82
PMTCT_EID_DSD	Sum of Infant Age disaggregates	109
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	10,057
TX_CURR_DSD	Age/Sex: 15-19 Male	167
TX_CURR_DSD	Age/Sex: 15-19 Female	170
TX_CURR_DSD	Sum of age/sex disaggregates	337
TX_CURR_DSD	Age/Sex: <1	27
TX_CURR_DSD	Age/Sex: <1-9	240
TX_CURR_DSD	Age/Sex: 10-14 Male	115
TX_CURR_DSD	Age/Sex: 10-14 Female	121
TX_CURR_DSD	Age/Sex: 20-24 Male	151
TX_CURR_DSD	Age/Sex: 50+ Male	934
TX_CURR_DSD	Age/Sex: 20-24 Female	416
TX_CURR_DSD	Age/Sex: 50+ Female	878
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	665
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	167
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,037
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	366
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,178
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	595
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	1,577
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male,	1,253



	Positive	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,144
TX_NEW_DSD	By Age/Sex: <1	40
TX_NEW_DSD	By Age/Sex: 1-9	53
TX_NEW_DSD	By Age/Sex: 10-14 Male	8
TX_NEW_DSD	By Age/Sex: 15-19 Male	116
TX_NEW_DSD	By Age/Sex: 20-24 Male	116
TX_NEW_DSD	By Age/Sex: 50+ Male	28
TX_NEW_DSD	By Age/Sex: 10-14 Female	8
TX_NEW_DSD	By Age/Sex: 15-19 Female	298
TX_NEW_DSD	By Age/Sex: 20-24 Female	298
TX_NEW_DSD	By Age/Sex: 50+ Female	7
TX_NEW_DSD	Sum of Age/Sex disaggregates	879
TX_NEW_DSD	Pregnancy status	1,630
TX_NEW_DSD	Breastfeeding status	407
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	133
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	49
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	161
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	118
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	156
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	124
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	197
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	234
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral	9,052



	load result documented in the patient medical record and /or laboratory records in the past 12 months.	
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	3
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	3
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	10
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	6
TX_PVLS_DSD	Undocumented Test Indication	22
TX_PVLS_DSD	Denominator: Indication: Routine	8,953
TX_PVLS_DSD	Denominator: Indication: Targeted	77
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	8
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	22
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	8
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	38
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	374
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	2,978
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	391
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	5,211
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,975
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,087
TX_RET_DSD	Numerator by Status: Pregnant	1,580
TX_RET_DSD	Numerator by Status: Breastfeeding	395
TX_RET_DSD	Denominator by Status: Pregnant	1,670





TX_RET_DSD	Denominator by Status: Breastfeeding	418
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	49
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	726
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	49
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,151
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	52
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	767
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	52
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,216
HTS_SELF_DSD	HTS_SELF_N_DSD	4,496
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19,	149



	Female, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	54
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	14
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	270
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	68
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	203
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	50
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	374
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	95
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	392
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	99
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	95
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	23
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	383
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	95
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	41
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	9



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	234
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	59
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	387
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	99
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	275
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	68
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	572
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	144
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	171
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	3,596
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	900
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	4,322
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	8,599



TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	430
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	430
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	3,010
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	4,729
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	216
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	216
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,513
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	2,377
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	860
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	7,739
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	432
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	3,890
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	9,554
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	381
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,528
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	1,528
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	6,117
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	9,554
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	9,554
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	8,502
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	96
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	946



TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	10
-----------	---	----

**Implementing Mechanism Details**

<b>Mechanism ID: 17268</b>	<b>Mechanism Name: Global HIV/AIDS Nursing Initiative</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 17268</b>		
<b>Mechanism Name: Global HIV/AIDS Nursing Initiative</b>		
<b>Prime Partner Name: Columbia University</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17341</b>	<b>Mechanism Name: Strengthening High Quality Laboratory Services Scale-Up for HIV Diagnosis, Care, Treatment and Monitoring in Malawi under the President's Emergency Plan for AIDS Relief (PEPFAR)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 5,671,540</b>	<b>Total Mechanism Pipeline: N/A</b>



<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 5,671,540</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	5,671,540

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	407,257
Renovation	200,000

**Budget Code Information**

<b>Mechanism ID:</b> 17341 <b>Mechanism Name:</b> Strengthening High Quality Laboratory Services Scale-Up for HIV Diagnosis, Care, Treatment and Monitoring in Malawi under <b>Prime Partner Name:</b> the President's Emergency Plan for AIDS Relief (PEPFAR) University Research Corporation, LLC		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	322,743
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	1,551,894
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	292,500
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	2,453,082
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	1,051,321





## Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,138
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	57,465
PMTCT_ART_TA	New on ART	1,260
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1,878
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	57,465
PMTCT_STAT_TA	Number of new ANC and L&D clients	66,809
PMTCT_STAT_TA	By Age (Denominator): 10-14	127
PMTCT_STAT_TA	By Age (Denominator): 15-19	15,204
PMTCT_STAT_TA	By Age (Denominator): 20-24	23,745
PMTCT_STAT_TA	By Age (Denominator): 50+	19
PMTCT_STAT_TA	By known positives: 15-19	447
PMTCT_STAT_TA	By known positives: 20-24	695
PMTCT_STAT_TA	By new positives: 15-19	298
PMTCT_STAT_TA	By new positives: 20-24	463
PMTCT_STAT_TA	By new negatives: 10-14	109
PMTCT_STAT_TA	By new negatives: 15-19	12,252
PMTCT_STAT_TA	By new negatives: 20-24	19,126
PMTCT_STAT_TA	By new negatives: 50+	12
PMTCT_STAT_TA	By Age (Numerator): 10-14	118
PMTCT_STAT_TA	By Age (Numerator): : 15-19	12,950
PMTCT_STAT_TA	By Age (Numerator): 20-24	20,312
PMTCT_STAT_TA	By Age (Numerator): 50+	13



PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	23,034
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	3,801
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	776
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	103
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	679
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	18,572
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	446
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	106
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	3,410
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	63
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	6
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	694
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	2
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	86
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	19,629
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	3,616
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	738
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	89
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	200,316
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	82
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male,	80



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,648
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	88
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	2,464
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	52
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,648
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	88
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	2,464
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	52
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	7
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	176
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	42
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	420
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,232
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	1,195
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	9



HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,843
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	74
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	3,478
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	57
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,869
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	76
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	3,511
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	58
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	138
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	259
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Negative	676
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	5,570
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	106
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	4,599
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	45



HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	37
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	102
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	37
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	102
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	34
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	32
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	926
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	124
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,219
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	146
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	926
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	124
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,219
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	146
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	187
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	31



HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	14
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	171
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) ANC: 10-14, Negative	3,547
HTC_TST_TA	Service Delivery Point (Facility) ANC: 10-14, Positive	61
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	5,578
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	119
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	8,862
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	197
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	619
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	605
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	8,041
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	495
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	14,958
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	401
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	8,041
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	495
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	14,958
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	401
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female,	149



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Negative	702
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Positive	26
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Negative	348
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Negative	2,852
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Positive	29
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	380
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	36
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	1,130
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	77
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	332
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	47
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	969
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	206
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	244
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	45
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	836
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	215



HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	119
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	63
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	1,070
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	436
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	892
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	25
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	1,000
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	7
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	803
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	34
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	856
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	48
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	581
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	31
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	733
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	54
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	329



HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	47
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	946
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	142
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Negative	85
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	1,097
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive	27
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	1,449
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	13
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	951
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	31
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	1,266
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	60
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	724
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	30
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	1,095
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	63
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	526



HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive	47
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	1,380
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	141
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	12,549
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	298
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	4,690
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	91
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	3,303
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	54
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	15,626
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	381
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	75
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	250
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	75
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Positive	1



HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	250
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	50
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative	93
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	43
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative	72
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	24
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	63
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Positive	5
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	7
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative	90
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Positive	20



HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative	4
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	14
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	18
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	8
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	14
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	3
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	9
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	4
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	17
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Negative	4,594
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Positive	225
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Negative	3,821
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Positive	85
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Negative	4,135

HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Positive	280
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Negative	3,274
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Positive	251
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Negative	3,013
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Positive	260
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Negative	2,799
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Positive	267
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Negative	1,691
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Positive	345
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Negative	3,605
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Positive	531
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	716
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	728
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	36
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	36
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases,	253



	during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	403
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	35
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	395
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	35
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	251
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	555
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	27
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	306
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	27
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	194



PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,703
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	2,168
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	535
PMTCT_EID_TA	Sum of Infant Age disaggregates	2,703
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	82,897
TX_CURR_TA	Age/Sex: 15-19 Male	1,278
TX_CURR_TA	Age/Sex: 15-19 Female	1,308
TX_CURR_TA	Sum of Age/Sex disaggregations	2,586
TX_CURR_TA	Age/Sex: <1	385
TX_CURR_TA	Age/Sex: 1-9	3,521
TX_CURR_TA	Age/Sex: 10-14 Male	1,665
TX_CURR_TA	Age/Sex: 10-14 Female	1,794
TX_CURR_TA	Age/Sex: 20-24 Male	1,172
TX_CURR_TA	Age/Sex: 50+ Male	7,211
TX_CURR_TA	Age/Sex: 20-24 Female	3,277
TX_CURR_TA	Age/Sex: 50+ Female	6,898
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	5,407
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	1,285
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	8,370
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	2,852
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	9,474
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	4,682
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female,	12,590



	Positive	
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	9,728
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	10,589
TX_NEW_TA	By Age/Sex: <1	74
TX_NEW_TA	By Age/Sex: 1-9	258
TX_NEW_TA	By Age/Sex: 10-14 Male	20
TX_NEW_TA	By Age/Sex: 15-19 Male	787
TX_NEW_TA	By Age/Sex: 20-24 Male	787
TX_NEW_TA	By Age/Sex: 50+ Male	158
TX_NEW_TA	By Age/Sex: 10-14 Female	23
TX_NEW_TA	By Age/Sex: 15-19 Female	988
TX_NEW_TA	By Age/Sex: 20-24 Female	1,212
TX_NEW_TA	By Age/Sex: 50+ Female	2
TX_NEW_TA	Sum of Age/Sex disaggregates	3,977
TX_NEW_TA	Pregnancy status	2,155
TX_NEW_TA	Breastfeeding status	576
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	582
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	296
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	704
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	729
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	685
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	774
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	1,020
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	1,490





	Positive	
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	50,523
TX_PVLS_TA	Denominator: Indication: Routine	49,009
TX_PVLS_TA	Denominator: Indication: Targeted	1,514
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,807
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	251
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,725
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	251
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	28,614
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	508
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	16,859
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	508
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	12,707
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	12,823
TX_RET_TA	Numerator by Status: Pregnant	202
TX_RET_TA	Numerator by Status: Breastfeeding	388
TX_RET_TA	Denominator by Status: Pregnant	203
TX_RET_TA	Denominator by Status: Breastfeeding	390
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment	676



	at 12 months after initiating ART)	
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,154
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	679
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,198
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	712
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,192
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	715
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,204
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	10,148
TB_PREV_TA	The number of ART patients who were newly started on	11,276



	TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	562
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	562
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	3,950
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	6,202
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	508
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	508
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	3,555
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	5,577
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	1,126
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	10,150
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	1,016
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	9,132
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	81,572
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	4,068
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	4,068
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	28,546
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	44,890
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	81,572
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	32,627
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of	48,945



	Specimen Sent]: Gene Xpert MTB / R if Assay	
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	72,655
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	803
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	8,077
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	37

### Implementing Mechanism Details

<b>Mechanism ID: 17451</b>	<b>Mechanism Name: Human Resources for Health (HRH) Capacity Building in Malawi under the President's Emergency Plan for AIDS Relief (PEPFAR)</b>	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Universtiy of Washington		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

<b>Total All Funding Sources: 3,652,578</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,652,578</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,652,578

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	50,000
----------------------------	--------



### Budget Code Information

<b>Mechanism ID:</b>	17451	
<b>Mechanism Name:</b>	Human Resources for Health (HRH) Capacity Building in Malawi	
<b>Prime Partner Name:</b>	under the President's Emergency Plan for AIDS Relief (PEPFAR) Universtiy of Washington	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	207,628
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	56,060
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	415,258
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	373,732
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	2,599,900

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17480</b>	<b>Mechanism Name: HP+</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Palladium Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

Key Populations: FSW	55,000
Focus Area:	Collection and use of strategic information on SWs and clients
Key Populations: MSM and TG	55,000
Focus Area:	Collection and use of strategic information
Condom programming	275,000

**Budget Code Information**

<b>Mechanism ID: 17480</b> <b>Mechanism Name: HP+</b> <b>Prime Partner Name: Palladium Group</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	150,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	315,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	65,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17487</b>	<b>Mechanism Name: Strengthening Malawi's Vital Statistics Systems through Civil Registration under PEPFAR</b>	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: National Registration Bureau Malawi		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	
<b>Total All Funding Sources: 450,000</b>		<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>		
<b>Total All Funding Sources and Applied Pipeline Amount: 450,000</b>		
<b>Funding Source</b>	<b>Funding Amount</b>	
GHP-State	450,000	

### Cross-Cutting Budget Attribution(s)

(No data provided.)





### Budget Code Information

<b>Mechanism ID:</b>	17487	
<b>Mechanism Name:</b>	Strengthening Malawi's Vital Statistics Systems through Civil	
<b>Prime Partner Name:</b>	Registration under PEPFAR National Registration Bureau Malawi	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	150,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	150,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	150,000

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17488</b>	<b>Mechanism Name: Improving Medical Education in Malawi under the President's Emergency Plan for AIDS Relief (PEPFAR)</b>	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of Malawi College of Medicine		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	
<b>Total All Funding Sources: 721,547</b>	<b>Total Mechanism Pipeline: N/A</b>	
<b>Applied Pipeline Amount: 0</b>		



<b>Total All Funding Sources and Applied Pipeline Amount: 721,547</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	721,547

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	484,957
----------------------------	---------

**Budget Code Information**

<b>Mechanism ID:</b>	17488	
<b>Mechanism Name:</b>	Improving Medical Education in Malawi under the President's	
<b>Prime Partner Name:</b>	Emergency Plan for AIDS Relief (PEPFAR)	
	University of Malawi College of Medicine	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	13,361
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	93,533
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	293,961
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	320,692

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**



<b>Mechanism ID: 17585</b>	<b>Mechanism Name: LINKAGES</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,059,245</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,059,245</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,059,245

### Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	1,128,198
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	2,632,466
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Gender: GBV	150,000



Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Motor Vehicles: Purchased	100,000
Adolescent Girls and Young Women (AGYW)	742,521

**Budget Code Information**

<b>Mechanism ID: 17585</b> <b>Mechanism Name: LINKAGES</b> <b>Prime Partner Name: FHI 360</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	1,189,652
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	184,592
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	97,873
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	1,243,173
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	1,039,118
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	6,255



## Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	560
PrEP_NEW_DSD	Female 15-19	84
PrEP_NEW_DSD	Female 20-24	168
PrEP_NEW_DSD	FSW	560
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	140
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	112
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	28
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	28
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	10,135
PP_PREV_DSD	Age/sex: 15-19 Male	535
PP_PREV_DSD	Age/sex: 20-24 Male	1,583
PP_PREV_DSD	Age/sex: 10-14 Female	539
PP_PREV_DSD	Age/sex: 15-19 Female	1,858
PP_PREV_DSD	Age/sex: 20-24 Female	1,713
PP_PREV_DSD	Sum of Age/Sex disaggregates	6,228
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	1,752
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	1,406
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	468
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	281
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	17,164
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key	3,819



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	299
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	13,046
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	12,337
HTC_TST_DSD	By Key Population: FSW, Negative	2,238
HTC_TST_DSD	By Key Population: FSW, Positive	1,218
HTC_TST_DSD	By Key Population: MSM, Negative	719
HTC_TST_DSD	By Key Population: MSM, Positive	59
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	97
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	2



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	97
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	36
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	548
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	54
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	260
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	41
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	1,737
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	203
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	1,369
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	163
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	56



HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	15
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	13
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	7
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	9

HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	2,502
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Positive	364
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	1,476
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	174
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	1,131
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	368
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	576
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	152
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	239
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	101
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	209
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	56
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	28
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	41
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	32
GEND_GBV_DSD	Number of people receiving post-GBV care	1,355
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence	1,116



	(Other Post-GBV Care)	
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	238
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	238
GEND_GBVDSD	15-19, Female, Physical and/or Emotional Violence	75
GEND_GBVDSD	15-19, Female, Sexual Violence (Post-Rape Care)	31
GEND_GBVDSD	15-19, Male, Physical and/or Emotional Violence	32
GEND_GBVDSD	15-19, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBVDSD	20-24, Female, Physical and/or Emotional Violence	310
GEND_GBVDSD	20-24, Female, Sexual Violence (Post-Rape Care)	101
GEND_GBVDSD	20-24, Male, Physical and/or Emotional Violence	87
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	432
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	100
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	68
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	62
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	7
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	5
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	39
GEND_GBVDSD	GEND_GBVDSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	6
TX_CURRDSD	Number of adults and children receiving antiretroviral therapy (ART)	1,834
TX_CURRDSD	Age/Sex: 15-19 Male	34
TX_CURRDSD	Age/Sex: 15-19 Female	30
TX_CURRDSD	Sum of age/sex disaggregates	64
TX_CURRDSD	Age/Sex: 20-24 Male	27



TX_CURR_DSD	Age/Sex: 50+ Male	169
TX_CURR_DSD	Age/Sex: 20-24 Female	75
TX_CURR_DSD	Age/Sex: 50+ Female	160
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	139
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	30
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	211
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	70
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	236
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	119
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	294
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	240
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	7,267
TX_CURR_TA	Age/Sex: 15-19 Male	120
TX_CURR_TA	Age/Sex: 15-19 Female	108
TX_CURR_TA	Sum of Age/Sex disaggregations	228
TX_CURR_TA	Age/Sex: 20-24 Male	115
TX_CURR_TA	Age/Sex: 50+ Male	653
TX_CURR_TA	Age/Sex: 20-24 Female	304
TX_CURR_TA	Age/Sex: 50+ Female	628
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	571
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	120
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female,	855



	Positive	
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	275
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	943
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	463
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	1,194
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	918
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,919
TX_NEW_DSD	By Age/Sex: 15-19 Male	52
TX_NEW_DSD	By Age/Sex: 20-24 Male	181
TX_NEW_DSD	By Age/Sex: 50+ Male	0
TX_NEW_DSD	By Age/Sex: 15-19 Female	54
TX_NEW_DSD	By Age/Sex: 20-24 Female	207
TX_NEW_DSD	By Age/Sex: 50+ Female	0
TX_NEW_DSD	Sum of Age/Sex disaggregates	494
TX_NEW_DSD	Pregnancy status	187
TX_NEW_DSD	Breastfeeding status	76
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	393
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	179
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	457
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	165
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	105
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	52



	Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	31
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	43
HTS_SELF_DSD	HTS_SELF_N_DSD	1,092
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	88
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	15
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	29
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	112
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	89
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	23
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	178
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	10



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	89
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	89
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	6
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	53
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	11
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	4
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	36
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	7
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	856
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	236

### Implementing Mechanism Details

<b>Mechanism ID: 17590</b>	<b>Mechanism Name: Project SOAR</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement



Prime Partner Name: Population Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 500,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 500,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	500,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 17590</b>		
<b>Mechanism Name: Project SOAR</b>		
<b>Prime Partner Name: Population Council</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	400,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>





Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	100,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18005</b>	<b>Mechanism Name: Challenge TB</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: KNCV Tuberculosis Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 1,640,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,640,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,640,000

### Cross-Cutting Budget Attribution(s)

Renovation	155,000
Motor Vehicles: Leased	48,000



**Budget Code Information**

<b>Mechanism ID:</b> 18005		
<b>Mechanism Name:</b> Challenge TB		
<b>Prime Partner Name:</b> KNCV Tuberculosis Foundation		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	1,485,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	155,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,650



TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	3,681
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	183
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	183
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,289
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,026
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	182
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,009
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	182
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,279
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,268
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	114
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with	1,249

	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	114
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	793
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	136,895
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	6,843
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	6,843
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	47,915
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	75,294
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	136,895
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	0
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	54,762
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	82,133
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	121,841
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	1,366
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	13,552
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	136

### Implementing Mechanism Details



<b>Mechanism ID: 18024</b>	<b>Mechanism Name: HIV Surveillance for Epidemic Control in Malawi under the President's Emergency Plan for AIDS Relief (PEPFAR)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,410,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,410,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,410,000

**Cross-Cutting Budget Attribution(s)**

Adolescent Girls and Young Women (AGYW)	500,000
---	---------

**Budget Code Information**

<b>Mechanism ID:</b>	18024	
<b>Mechanism Name:</b>	HIV Surveillance for Epidemic Control in Malawi under the President's Emergency Plan for AIDS Relief (PEPFAR)	
<b>Prime Partner Name:</b>	University of Washington	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	2,156,322
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Treatment	PDTX	1,253,678
-----------	------	-----------

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 18025</b>	<b>Mechanism Name: Achieving HIV Epidemic Control through Scaling up Quality Testing, Care and Treatment in Malawi under the President's Plan for AIDS Relief (PEPFAR)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Lighthouse	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 6,295,974</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 6,295,974</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	6,295,974

**Cross-Cutting Budget Attribution(s)**

Key Populations: MSM and TG	144,303
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information





Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	25,468
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Motor Vehicles: Purchased	405,000
Human Resources for Health	3,944,762

**Budget Code Information**

<b>Mechanism ID: 18025</b> <b>Mechanism Name: Achieving HIV Epidemic Control through Scaling up Quality</b> <b>Prime Partner Name: Testing, Care and Treatment in Malawi under the President's Plan for AIDS Relief (PEPFAR)</b> <b>Lighthouse</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	143,309
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	420,847
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	299,279
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	137,563



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	1,645,335
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	66,162
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	82,537
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	3,057,768
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	443,174

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,903
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	31,389
PMTCT_ART_DSD	New on ART	744
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,159
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	31,389
PMTCT_STAT_DSD	Number of new ANC and L&D clients	33,037
PMTCT_STAT_DSD	By Age (Denominator): 10-14	81
PMTCT_STAT_DSD	By Age (Denominator): <15-19	7,451



PMTCT_STAT_DSD	By Age (Denominator): 20-24	11,627
PMTCT_STAT_DSD	By Age (Denominator): 50+	23
PMTCT_STAT_DSD	By Number of known positives: 10-14	4
PMTCT_STAT_DSD	By Number of known positives: 15-19	270
PMTCT_STAT_DSD	By Number of known positives: 20-24	424
PMTCT_STAT_DSD	By Number of new positives: 10-14	1
PMTCT_STAT_DSD	By Number of new positives: 15-19	181
PMTCT_STAT_DSD	By Number of new positives: 20-24	284
PMTCT_STAT_DSD	By Number of new negative: 10-14	70
PMTCT_STAT_DSD	By Number of new negative: 15-19	6,625
PMTCT_STAT_DSD	By Number of new negative: 20-24	10,339
PMTCT_STAT_DSD	By Number of new negative: 50+	23
PMTCT_STAT_DSD	By Age (Numerator): 10-14	74
PMTCT_STAT_DSD	By Age (Numerator): 15-19	7,078
PMTCT_STAT_DSD	By Age (Numerator): 20-24	11,044
PMTCT_STAT_DSD	By Age (Numerator): 50+	24
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	11,290
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	2,078
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	425
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	62
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	410
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	10,038
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	275
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	74
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	1,852
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	52
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	18



	35-39, Female, Known at Entry Positive	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	381
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	10
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	2
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	56
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	10,722
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	1,981
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	407
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	59
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	500
PrEP_NEW_DSD	Female 15-19	150
PrEP_NEW_DSD	Female 20-24	350
PrEP_NEW_DSD	FSW	500
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	4,871
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,871
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	229,158
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	234
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14,	6



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	227
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	2,612
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	168
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	4,516
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	134
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	2,612
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	168
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	4,516
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	134
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	38
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	543
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	51
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	135
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	1,078
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14,	1,429



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	1,392
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,973
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	91
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	4,004
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	78
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,973
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	91
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	4,004
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	78
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	303
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	823
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	16



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	6,576
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	130
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	8,013
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	124
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	87
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	164
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	87
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	164
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female,	31



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	959
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	159
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,345
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	187
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	959
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	159
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,345
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	187
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	297
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	71
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	162
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	2,396





HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	4,034
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	72
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	8,781
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	156
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	700
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	683
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	7,524
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	427
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	17,851
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	375
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	7,524
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	427
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	17,851
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	375
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	146
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male,	780



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	398
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	3,205
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	61
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	275
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	1,600
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	130
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	250
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	1,368
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	317
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	181
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	46
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	1,170
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	333
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	101
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	67



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	1,513
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	638
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	1,212
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	2,995
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	88
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	1,097
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	89
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	2,559
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	215
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	795
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	2,191
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	224
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	446
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	106
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49,	2,824



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	431
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	1,127
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	952
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	1,620
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	858
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	1,388
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	94
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	624
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	1,187
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	98
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	352
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	64



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	1,529
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	180
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	13,270
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	238
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	6,257
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	102
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	2,863
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	11,795
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	163
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	76
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	278
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	76
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male,	278



	Negative	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	56
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	157
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	51
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	132
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	35
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	112
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	148
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	57



	Positive	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	55
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	93
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	49
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	34
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	67
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	41
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	87



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	4,320
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	214
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	4,221
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	102
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	3,890
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	262
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	3,608
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	243
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	2,827
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	246
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	3,084
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	260
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	1,587
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	320
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	3,982
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	489





	Male, Positive	
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,541
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,555
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	129
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,396
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	129
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	887
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	131
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,402
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	130
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	892
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,383
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	67



	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	760
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	68
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	485
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,905
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,523
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	382
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,905
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	83,677
TX_CURR_DSD	Age/Sex: 15-19 Male	1,371
TX_CURR_DSD	Age/Sex: 15-19 Female	1,345
TX_CURR_DSD	Sum of age/sex disaggregates	2,716
TX_CURR_DSD	Age/Sex: <1	350
TX_CURR_DSD	Age/Sex: <1-9	3,538
TX_CURR_DSD	Age/Sex: 10-14 Male	1,905
TX_CURR_DSD	Age/Sex: 10-14 Female	2,039
TX_CURR_DSD	Age/Sex: 20-24 Male	1,097
TX_CURR_DSD	Age/Sex: 50+ Male	7,409
TX_CURR_DSD	Age/Sex: 20-24 Female	3,103
TX_CURR_DSD	Age/Sex: 50+ Female	7,132
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29,	5,201



	Female, Positive	
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,277
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	8,250
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,848
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	9,646
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	4,667
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	12,824
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	9,675
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	9,952
TX_NEW_DSD	By Age/Sex: <1	131
TX_NEW_DSD	By Age/Sex: 1-9	349
TX_NEW_DSD	By Age/Sex: 10-14 Male	49
TX_NEW_DSD	By Age/Sex: 15-19 Male	734
TX_NEW_DSD	By Age/Sex: 20-24 Male	733
TX_NEW_DSD	By Age/Sex: 50+ Male	196
TX_NEW_DSD	By Age/Sex: 10-14 Female	51
TX_NEW_DSD	By Age/Sex: 15-19 Female	799
TX_NEW_DSD	By Age/Sex: 20-24 Female	967
TX_NEW_DSD	By Age/Sex: 50+ Female	15
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,544
TX_NEW_DSD	Pregnancy status	1,627
TX_NEW_DSD	Breastfeeding status	429
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	447
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	351



	Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	541
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	837
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	527
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	881
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	662
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,682
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	51,383
TX_PVLS_DSD	Denominator: Indication: Routine	49,842
TX_PVLS_DSD	Denominator: Indication: Targeted	1,541
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	252
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	514
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	253
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	514
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,709
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	17,140
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,780
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	29,221



TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	11,799
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	11,910
TX_RET_DSD	Numerator by Status: Pregnant	190
TX_RET_DSD	Numerator by Status: Breastfeeding	342
TX_RET_DSD	Denominator by Status: Pregnant	212
TX_RET_DSD	Denominator by Status: Breastfeeding	433
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	504
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,096
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	507
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,692
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	524
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,136
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	527

	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,723
HTS_SELF_DSD	HTS_SELF_N_DSD	4,401
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	354
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	62
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	289
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	115
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	449
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	78
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	359
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	144
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	90
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	78
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	717
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	144
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	39



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	358
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	71
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	39
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	38
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	358
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	71
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	25
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	22
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	211
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	42
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	17
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	15
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	145
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	29
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	3,451
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	950
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of	19,723



	Isoniazid Preventive Therapy (IPT) during the reporting period	
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	21,914
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,096
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,096
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	7,670
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	12,052
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	986
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	986
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	6,903
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	10,848
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	2,191
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	19,723
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	1,973
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	17,750
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	129,078
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	6,455
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	6,454
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	45,180
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	70,989
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	129,078





TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	51,644
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	77,434
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	114,883
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	1,288
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	12,777
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	130

### Implementing Mechanism Details

<b>Mechanism ID: 18028</b>	<b>Mechanism Name: Malawi Scholarship Program</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: World Learning	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

### Cross-Cutting Budget Attribution(s)

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 18028		
<b>Mechanism Name:</b> Malawi Scholarship Program		
<b>Prime Partner Name:</b> World Learning		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	790,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18045</b>	<b>Mechanism Name: Bringing VMMC Services to Scale in the MDF</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 439,176</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 439,176</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	439,176

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 18045</b>		
<b>Mechanism Name: Bringing VMMC Services to Scale in the MDF</b>		
<b>Prime Partner Name: JHPIEGO</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	439,176
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	5,050
VMMC_CIRC_DSD	By Age: 10-14	1,116
VMMC_CIRC_DSD	By Age: 15-19	1,928
VMMC_CIRC_DSD	By Age: 20-24	981
VMMC_CIRC_DSD	By Age: 25-29	474
VMMC_CIRC_DSD	By Age: 50+	50
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	4,075
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	4,549
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	4,554
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	496
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	167
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	167
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	167

### Implementing Mechanism Details

<b>Mechanism ID: 18063</b>	<b>Mechanism Name: Global Health Supply Chain Program (GHSC) Procurement and Supply Management (PSM)</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,006,740</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,006,740</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,006,740

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18063	
<b>Mechanism Name:</b>	Global Health Supply Chain Program (GHSC) Procurement and Supply Management (PSM)	
<b>Prime Partner Name:</b>	Global Health Supply Chain Program	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	212,500
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	2,906,740
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	69,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	105,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0





Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	707,750
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	5,750

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18142</b>	<b>Mechanism Name: SIFPO 2</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount

### Cross-Cutting Budget Attribution(s)

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 18142 <b>Mechanism Name:</b> SIFPO 2 <b>Prime Partner Name:</b> Population Services International		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18234</b>	<b>Mechanism Name: EQUIP</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Right To Care, South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 4,163,723</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,163,723</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-USAID	4,163,723

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	100,000
Focus Area:	Post GBV Care
Sub Area:	Implementation
Renovation	156,000
Motor Vehicles: Purchased	135,000

**Budget Code Information**

<b>Mechanism ID: 18234</b>		
<b>Mechanism Name: EQUIP</b>		
<b>Prime Partner Name: Right To Care, South Africa</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	337,463
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	HVTB	108,513
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	241,052
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	1,002,338
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,887,851
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	586,506

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,953
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	48,864
PMTCT_ART_DSD	New on ART	1,213
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,740
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	48,864
PMTCT_STAT_DSD	Number of new ANC and L&D clients	51,070
PMTCT_STAT_DSD	By Age (Denominator): 10-14	116
PMTCT_STAT_DSD	By Age (Denominator): <15-19	11,520
PMTCT_STAT_DSD	By Age (Denominator): 20-24	17,974
PMTCT_STAT_DSD	By Age (Denominator): 50+	31
PMTCT_STAT_DSD	By Number of known positives: 10-14	3

PMTCT_STAT_DSD	By Number of known positives: 15-19	412
PMTCT_STAT_DSD	By Number of known positives: 20-24	645
PMTCT_STAT_DSD	By Number of new positives: 10-14	1
PMTCT_STAT_DSD	By Number of new positives: 15-19	286
PMTCT_STAT_DSD	By Number of new positives: 20-24	449
PMTCT_STAT_DSD	By Number of new negative: 10-14	105
PMTCT_STAT_DSD	By Number of new negative: 15-19	10,321
PMTCT_STAT_DSD	By Number of new negative: 20-24	16,097
PMTCT_STAT_DSD	By Number of new negative: 50+	39
PMTCT_STAT_DSD	By Age (Numerator): 10-14	113
PMTCT_STAT_DSD	By Age (Numerator): 15-19	11,019
PMTCT_STAT_DSD	By Age (Numerator): 20-24	17,190
PMTCT_STAT_DSD	By Age (Numerator): 50+	37
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	17,457
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	3,215
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	660
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	97
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	628
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	15,633
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	437
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	117
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	2,884
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	82
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	23
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	592



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	18
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	4
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	87
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	1
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	16,696
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	3,080
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	635
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	94
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	177,679
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	49
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	48
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,762
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	121
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	2,791
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	95
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,762
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	121





	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	2,791
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	95
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	158
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	28
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	224
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	833
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	867
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,229
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	82
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	3,042
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	87
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24,	1,341



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	87
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	3,212
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	95
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1,271
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	832
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	210
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	2,641
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	1,903
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	63
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male,	158



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	63
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	158
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	31
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1,303
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	216
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,551
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	218
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,303



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	216
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,551
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	218
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	150
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	142
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	3,083
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	91
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	4,485
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	128
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	7,996
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	215
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	262
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	255
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female,	7,167



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	511
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	13,537
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	467
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	7,167
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	511
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	13,537
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	467
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	142
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	528
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	59
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	151
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	1,204
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	540
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	94
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	810
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	74



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	487
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	114
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	694
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	174
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	356
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	105
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	592
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	184
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	199
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	139
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	765
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	350
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	1,020
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	60
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	846
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	919



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	726
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	667
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	621
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	75
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	375
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	88
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	800
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	145
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	52
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	955
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	1,488
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34,	675



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	48
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	1,390
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	94
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	679
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	1,166
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	92
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	1,508
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	104
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	1,688
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	171
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	11,110
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	289
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	3,844
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	90
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	2,563
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	63





	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	12,686
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	398
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	113
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	309
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	113
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	309
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	98
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	89
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	90
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male,	76



	Negative	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	64
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	14
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	64
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	36
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	83
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	45
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34,	40



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	36
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	29
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	31
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	34
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	40
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	4,216
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	249
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	2,842
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	105
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	3,797
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	301



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	2,432
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	253
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	2,760
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	286
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	2,080
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	266
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	1,549
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	369
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	2,682
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	509
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,365
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,378
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	66
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	750
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	63



TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	486
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	66
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	755
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	63
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	494
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	577
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	25
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	318
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	30
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	209
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within	2,949



	12 months of birth during the reporting period	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,356
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	593
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,949
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	146,487
TX_CURR_DSD	Age/Sex: 15-19 Male	2,237
TX_CURR_DSD	Age/Sex: 15-19 Female	2,326
TX_CURR_DSD	Sum of age/sex disaggregates	4,563
TX_CURR_DSD	Age/Sex: <1	260
TX_CURR_DSD	Age/Sex: <1-9	2,352
TX_CURR_DSD	Age/Sex: 10-14 Male	1,022
TX_CURR_DSD	Age/Sex: 10-14 Female	1,055
TX_CURR_DSD	Age/Sex: 20-24 Male	2,406
TX_CURR_DSD	Age/Sex: 50+ Male	12,759
TX_CURR_DSD	Age/Sex: 20-24 Female	6,255
TX_CURR_DSD	Age/Sex: 50+ Female	12,019
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	10,894
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	2,630
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	16,433
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	5,663
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	17,636
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	9,181
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	22,837



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	18,522
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	10,939
TX_NEW_DSD	By Age/Sex: <1	54
TX_NEW_DSD	By Age/Sex: 1-9	143
TX_NEW_DSD	By Age/Sex: 10-14 Male	19
TX_NEW_DSD	By Age/Sex: 15-19 Male	948
TX_NEW_DSD	By Age/Sex: 20-24 Male	948
TX_NEW_DSD	By Age/Sex: 50+ Male	156
TX_NEW_DSD	By Age/Sex: 10-14 Female	19
TX_NEW_DSD	By Age/Sex: 15-19 Female	1,088
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,331
TX_NEW_DSD	By Age/Sex: 50+ Female	22
TX_NEW_DSD	Sum of Age/Sex disaggregates	4,531
TX_NEW_DSD	Pregnancy status	2,278
TX_NEW_DSD	Breastfeeding status	610
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	668
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	274
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	817
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	653
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	797
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	689
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	996
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,317



TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	11,607
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	11,717
TX_RET_DSD	Numerator by Status: Pregnant	189
TX_RET_DSD	Numerator by Status: Breastfeeding	348
TX_RET_DSD	Denominator by Status: Pregnant	191
TX_RET_DSD	Denominator by Status: Breastfeeding	317
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	442
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,314
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	444
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,407
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	460
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,347
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	461





	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,449
HTS_SELF_DSD	HTS_SELF_N_DSD	2,759
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	222
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	39
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	181
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	281
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	49
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	225
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	91
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	56
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	49
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	450
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	91
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	25



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	24
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	224
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	25
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	24
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	224
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	45
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	16
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	14
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	133
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	27
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	10
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	91
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	18
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	2,163
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	596
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of	11,847

	Isoniazid Preventive Therapy (IPT) during the reporting period	
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	13,234
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	655
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	655
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	4,604
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	7,235
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	590
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	590
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	4,146
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	6,521
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	1,304
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	11,845
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	1,185
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	10,662
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	73,709
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	3,685
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	3,685
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	25,798
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	40,541
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	73,709



TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	30,030
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	43,679
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	65,612
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	735
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	7,297
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	65

### Implementing Mechanism Details

<b>Mechanism ID: 18244</b>	<b>Mechanism Name: Addressing unmet need in HIV Testing Services (HTS) through effective delivery models under PEPFAR</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 6,476,430</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 6,476,430</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	6,476,430

### Cross-Cutting Budget Attribution(s)

Key Populations: FSW	41,112
Focus Area:	Implementation of core HIV prevention interventions



	for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	232,970
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Human Resources for Health	471,046
Adolescent Girls and Young Women (AGYW)	750,000

**Budget Code Information**

<b>Mechanism ID:</b>	18244	
<b>Mechanism Name:</b>	Addressing unmet need in HIV Testing Services (HTS) through effective delivery models under PEPFAR	
<b>Prime Partner Name:</b>	JHPIEGO	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	64,732
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	25,161
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	PDCS	99,484
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	425,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	948,137
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	75,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	4,328,331
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	510,585

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	22,698
PP_PREV_DSD	Age/sex: 15-19 Male	154
PP_PREV_DSD	Age/sex: 20-24 Male	385
PP_PREV_DSD	Age/sex: 50+ Male	227
PP_PREV_DSD	Age/sex: 15-19 Female	385
PP_PREV_DSD	Age/sex: 20-24 Female	847
PP_PREV_DSD	Age/sex: 50+ Female	304
PP_PREV_DSD	Sum of Age/Sex disaggregates	2,302
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	1,519
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	1,839



PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	3,693
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	1,905
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	4,281
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	1,670
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	977
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	4,512
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,759
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	36
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	223
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,500
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	91,024
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	41
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	100



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	41
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	100
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	86
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	5,516
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	122
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	86
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	5,516
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	122
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	2





HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	207
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	749
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	732
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	517
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1,436
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	517
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,436
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	161
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	3

HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	452
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	3,455
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	20
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	1,306
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	32
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	20
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	1,306
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	32
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	28
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	767
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	4



HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	56
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	54
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	618
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	835
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	618
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	835
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	252
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	58



HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	31
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	256
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	1
HTC_TST_DSD	By Key Population: FSW, Negative	244
HTC_TST_DSD	By Key Population: FSW, Positive	88
HTC_TST_DSD	By Key Population: MSM, Negative	113
HTC_TST_DSD	By Key Population: MSM, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	10
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	156
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	1,211
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	162
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	156
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	1,211
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	162
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	3



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	51
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	47
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	580
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	559
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	2,492
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	5,094
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	78
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	2,492
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	5,094



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	83
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	44
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	246
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	348
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	2,664
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	314
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	2,097
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	112
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	517
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	81
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	2,382
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	139
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	41
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	192
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29,	113



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	1,350
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	102
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	1,154
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	74
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	988
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	46
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	1,273
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	74
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	17
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	1



	Female, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	27
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	20
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	299
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29,	1,114



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	63
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	270
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	953
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	149
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	196
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	815
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	158
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	1,051
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	301
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	104
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	275
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	22



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	95
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	235
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	68
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	201
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	38
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	24
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	260
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	103
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	243
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	865
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34,	219



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	739
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	159
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	633
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	91
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	815
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	150
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	128
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	6



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	109
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	141
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	2



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	5
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	3
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	1



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	1,328
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	1,328
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	1,196
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	1,136
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	869
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	972
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	488
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	1,253
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29,	946



	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Positive	146
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	1,669
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	163
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	377
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	214
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	821
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	279
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	252
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	760
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	228
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	46
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	811
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	422
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	845
TB_STAT_DSD	Total number of registered new and relapsed TB cases,	873



	during the reporting period.	
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	42
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	465
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	42
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	296
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	43
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	481
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	43
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	306
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	420
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	21
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	230





	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	21
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	148
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	14,154
TX_CURR_DSD	Age/Sex: 15-19 Male	245
TX_CURR_DSD	Age/Sex: 15-19 Female	232
TX_CURR_DSD	Sum of age/sex disaggregates	477
TX_CURR_DSD	Age/Sex: <1	15
TX_CURR_DSD	Age/Sex: <1-9	135
TX_CURR_DSD	Age/Sex: 10-14 Male	78
TX_CURR_DSD	Age/Sex: 10-14 Female	90
TX_CURR_DSD	Age/Sex: 20-24 Male	217
TX_CURR_DSD	Age/Sex: 50+ Male	1,257
TX_CURR_DSD	Age/Sex: 20-24 Female	581
TX_CURR_DSD	Age/Sex: 50+ Female	1,158
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	1,009
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	246
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	1,574
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	558
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	1,770
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	924



TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	2,234
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	1,831
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,228
TX_NEW_DSD	By Age/Sex: <1	17
TX_NEW_DSD	By Age/Sex: 1-9	41
TX_NEW_DSD	By Age/Sex: 10-14 Male	6
TX_NEW_DSD	By Age/Sex: 15-19 Male	193
TX_NEW_DSD	By Age/Sex: 20-24 Male	194
TX_NEW_DSD	By Age/Sex: 50+ Male	55
TX_NEW_DSD	By Age/Sex: 10-14 Female	5
TX_NEW_DSD	By Age/Sex: 15-19 Female	138
TX_NEW_DSD	By Age/Sex: 20-24 Female	180
TX_NEW_DSD	By Age/Sex: 50+ Female	3
TX_NEW_DSD	Sum of Age/Sex disaggregates	774
TX_NEW_DSD	Pregnancy status	917
TX_NEW_DSD	Breastfeeding status	242
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	74
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	99
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	89
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	234
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	84
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	246
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	107



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	463
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	6,323
TX_PVLS_DSD	Denominator: Indication: Routine	6,133
TX_PVLS_DSD	Denominator: Indication: Targeted	190
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	32
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	63
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	32
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	63
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	213
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	2,136
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	220
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	3,564
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,178
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,195
TX_RET_DSD	Numerator by Status: Pregnant	9
TX_RET_DSD	Numerator by Status: Breastfeeding	6
TX_RET_DSD	Denominator by Status: Pregnant	9
TX_RET_DSD	Denominator by Status: Breastfeeding	6
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of	64



	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,419
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	65
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	630
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	65
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,429
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	66
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	635
HTS_SELF_DSD	HTS_SELF_N_DSD	112,824
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	9,070
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19,	1,590



	Female, Unassisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	7,417
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	2,952
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	11,504
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	1,995
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	9,188
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	3,705
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	2,301
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	1,995
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	18,391
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	3,705
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	1,013
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	983
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	9,179
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	1,825
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	1,013
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	983
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	9,179

	Male, Directly-Assisted	
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	1,825
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	640
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	585
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	5,422
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	1,086
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	413
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	399
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	3,727
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	741
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	88,456
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	24,368
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	5,876
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	6,531
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	327
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	327



TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	2,285
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	3,592
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	293
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	293
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	2,057
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	3,233
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	654
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	5,877
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	588
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	5,288
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	9,630
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	455
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	745
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	2,909
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	5,521
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	9,628
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	5,295
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	4,333
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	6,655
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	74
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	2,870



TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	31
-----------	---	----

**Implementing Mechanism Details**

<b>Mechanism ID: 18245</b>	<b>Mechanism Name: Strengthening Human Resource For Health capacity to Deliver Quality HIV/AIDS services in high burden sites under PEPFAR</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Christian Health Association of Malawi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,700,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,700,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,700,000

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	1,700,000
----------------------------	-----------

**Budget Code Information**

<b>Mechanism ID:</b>	18245	
<b>Mechanism Name:</b>	Strengthening Human Resource For Health capacity to Deliver Quality HIV/AIDS services in high burden sites under PEPFAR	
<b>Prime Partner Name:</b>	Christian Health Association of Malawi	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>





Prevention	HVCT	89,474
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	1,252,630
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PCTX	357,896

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18246</b>	<b>Mechanism Name: Quality Improvement Capacity for Impact Project (QICIP)</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: Health Research Inc./New York State Department of Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

### Cross-Cutting Budget Attribution(s)

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 18246		
<b>Mechanism Name:</b> Quality Improvement Capacity for Impact Project (QICIP)		
<b>Prime Partner Name:</b> Health Research Inc./New York State Department of Health		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<p><b>Mechanism ID: 18247</b></p>	<p><b>Mechanism Name: Technical Assistance to Provide High-Quality Voluntary Medical Male Circumcision (VMMC) Services to Programs Supported by the President's Emergency Plan for AIDS Relief (PEPFAR)</b></p>
-----------------------------------	---



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,350,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,350,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,350,000

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	908,533
Motor Vehicles: Purchased	135,000

**Budget Code Information**

<b>Mechanism ID:</b>	<b>18247</b>	
<b>Mechanism Name:</b>	<b>Technical Assistance to Provide High-Quality Voluntary Medical Male Circumcision (VMMC) Services to Programs Supported by</b>	
<b>Prime Partner Name:</b>	<b>the President's Emergency Plan for AIDS Relief (PEPFAR)</b>	
	<b>JHPIEGO</b>	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	4,350,000

**Implementing Mechanism Indicator Information**



Indicator Number	Label	2019
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	50,015
VMMC_CIRC_DSD	By Age: 10-14	10,051
VMMC_CIRC_DSD	By Age: 15-19	19,951
VMMC_CIRC_DSD	By Age: 20-24	10,151
VMMC_CIRC_DSD	By Age: 25-29	4,900
VMMC_CIRC_DSD	By Age: 50+	453
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	40,606
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	45,506
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	49,515
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	500
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	1,503
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	1,503
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	1,503
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	50,000
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	10,211
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	10,211
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	1,470
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	7,913
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34,	6,769



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	30
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	5,790
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	7,463
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	61

**Implementing Mechanism Details**

<b>Mechanism ID: 18256</b>	<b>Mechanism Name: Construction and Renovation</b>
Funding Agency: State/AF	Procurement Type: Contract
Prime Partner Name: Regional Procurement Support Office/Frankfurt	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 542,825</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 33,418</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 576,243</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	542,825

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 18256		
<b>Mechanism Name:</b> Construction and Renovation		
<b>Prime Partner Name:</b> Regional Procurement Support Office/Frankfurt		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	542,825
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18279</b>	<b>Mechanism Name: Coordinating Comprehensive Care for Children (4Children)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted



Approved



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 920,192</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 920,192</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	920,192

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	107,093
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Education	50,000
Economic Strengthening	50,000

**Budget Code Information**

<b>Mechanism ID:</b>	18279	
<b>Mechanism Name:</b>	Coordinating Comprehensive Care for Children (4Children)	
<b>Prime Partner Name:</b>	Catholic Relief Services	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	920,192
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	13,902
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,641
OVC_SERV_DSD	Age/Sex: 15-17 Male	1,532
OVC_SERV_DSD	By: Age/sex: Male 18-24	296
OVC_SERV_DSD	By: Age/sex: Male 25+	474
OVC_SERV_DSD	Age/Sex: 10-14 Female	3,282
OVC_SERV_DSD	Age/Sex: 15-17 Female	3,063
OVC_SERV_DSD	By: Age/sex: 18-24 Female	385
OVC_SERV_DSD	By: Age/sex: 25+ Female	1,806
OVC_SERV_DSD	Sum of Age/Sex disaggregates	9,518
OVC_SERV_DSD	Age/Sex: 1-9	1,422
OVC_SERV_DSD	Program Completion: Active	6,931
OVC_SERV_DSD	Program Completion: Graduation	6,971
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years	10,423



	old) whose HIV status is known or unknown by the OVC implementing partner.	
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	13,902

**Implementing Mechanism Details**

<b>Mechanism ID: 18303</b>	<b>Mechanism Name: Health Communication for Life</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18303	
<b>Mechanism Name:</b>	Health Communication for Life	
<b>Prime Partner Name:</b>	FHI 360	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18305</b>	<b>Mechanism Name: HRH 2030</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Chemonics International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 1,652,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	



<b>Total All Funding Sources and Applied Pipeline Amount: 1,652,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,652,000

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	1,652,000
----------------------------	-----------

**Budget Code Information**

<b>Mechanism ID: 18305</b>		
<b>Mechanism Name: HRH 2030</b>		
<b>Prime Partner Name: Chemonics International</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Governance and Systems	OHSS	269,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	456,390
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	470,220
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	456,390





### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18351</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 18479</b>	<b>Mechanism Name: SIFPO 2 BLM</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Marie Stopes International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 18479</b>
----------------------------



<b>Mechanism Name: SIFPO 2 BLM</b>		
<b>Prime Partner Name: Marie Stopes International</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18544</b>	<b>Mechanism Name: Achieving HIV Epidemic Control through Scaling Up Quality Testing, Care and Treatment in Malawi under the Presidents Emergency Fund for AIDS Relief (PEPFAR) - Pivot 2</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 15,310,368</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 15,310,368</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	15,310,368

### Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	279,349
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	94,322
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Collection and use of strategic information on SWs and clients
Water	100,000
Motor Vehicles: Purchased	525,000
Adolescent Girls and Young Women (AGYW)	450,000



Human Resources for Health	9,426,443
----------------------------	-----------

**Budget Code Information**

<b>Mechanism ID:</b> 18544 <b>Mechanism Name:</b> Achieving HIV Epidemic Control through Scaling Up Quality <b>Prime Partner Name:</b> Testing, Care and Treatment in Malawi under the Presidents Emergency Fund for AIDS Relief (PEPFAR) - Pivot 2 Elizabeth Glaser Pediatric AIDS Foundation		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	270,813
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	1,014,616
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	581,673
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	365,088
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	3,066,081
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	270,063
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	425,038
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	8,338,800



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	978,196

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	15,530
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	167,655
PMTCT_ART_DSD	New on ART	5,625
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	9,905
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	167,655
PMTCT_STAT_DSD	Number of new ANC and L&D clients	176,455
PMTCT_STAT_DSD	By Age (Denominator): 10-14	407
PMTCT_STAT_DSD	By Age (Denominator): <15-19	39,801
PMTCT_STAT_DSD	By Age (Denominator): 20-24	62,089
PMTCT_STAT_DSD	By Age (Denominator): 50+	150
PMTCT_STAT_DSD	By Number of known positives: 10-14	26
PMTCT_STAT_DSD	By Number of known positives: 15-19	2,353
PMTCT_STAT_DSD	By Number of known positives: 20-24	3,671
PMTCT_STAT_DSD	By Number of known positives: 50+	9
PMTCT_STAT_DSD	By Number of new positives: 10-14	14
PMTCT_STAT_DSD	By Number of new positives: 15-19	1,334
PMTCT_STAT_DSD	By Number of new positives: 20-24	2,081
PMTCT_STAT_DSD	By Number of new positives: 50+	4
PMTCT_STAT_DSD	By Number of new negative: 10-14	353



PMTCT_STAT_DSD	By Number of new negative: 15-19	34,117
PMTCT_STAT_DSD	By Number of new negative: 20-24	53,231
PMTCT_STAT_DSD	By Number of new negative: 50+	122
PMTCT_STAT_DSD	By Age (Numerator): 10-14	384
PMTCT_STAT_DSD	By Age (Numerator): 15-19	37,810
PMTCT_STAT_DSD	By Age (Numerator): 20-24	58,986
PMTCT_STAT_DSD	By Age (Numerator): 50+	141
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	60,282
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	11,113
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	2,278
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	335
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	3,570
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	51,685
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	2,019
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	658
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	9,535
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	376
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	144
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	1,952
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	78
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	22
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	290



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	11
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	57,275
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	10,571
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	2,165
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	323
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,444
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,444
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	617,349
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	259
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	250
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	4,691
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	310
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	5,393
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	160





HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	4,691
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	310
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	5,393
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	160
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	101
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	623
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	149
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	1,225
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	5,493
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	156
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	5,322
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	153
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	5,334
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	379
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	7,101



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	206
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	5,334
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	379
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	7,101
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	206
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	125
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	945
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	94
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	3,134
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	86
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	25,186
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	709
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	18,947
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	208
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	133



HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	256
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	133
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	256
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	252
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	244
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	3,348
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	568
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	3,672
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	522



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	3,348
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	568
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	3,672
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	522
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	1,227
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	283
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	145
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,186
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	98
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	746
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	7,679
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	321
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	13,805
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	573
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	25,306
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	1,120
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	2,567



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	2,488
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	26,046
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	1,831
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	32,422
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	961
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	26,046
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	1,906
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	32,422
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	1,021
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	614
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	52
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	2,359
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	224
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	1,460
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	11,770
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	269



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	1,377
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	241
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	6,604
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	580
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	1,238
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	293
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	5,655
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	1,400
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	900
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	278
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	4,838
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	1,486
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	507
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	349
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	6,228
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	2,844
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	2,959



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	162
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	3,354
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	100
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	2,671
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	194
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	2,867
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	255
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	1,944
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	187
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	2,449
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	263
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	1,091
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	255
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	3,164
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	502
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	1,207
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	27

HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	3,573
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	207
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	5,092
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	159
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	3,213
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	233
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	4,358
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	399
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	2,335
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	225
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	3,725
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	423
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	1,307
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	284
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	4,796
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	805
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	33,160





HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	1,441
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	10,482
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	521
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	6,020
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	338
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	34,834
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	1,601
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	334
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	744
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	334
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	744
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	289
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	18



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	623
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	34
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	256
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	532
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	95
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	191
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	450
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	102
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	100
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	591
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	203
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	4
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	105
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	25



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	102
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	141
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	90
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	123
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	56
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	93
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	76
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	135
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	18,364



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	1,052
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	12,697
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	399
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	16,542
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	1,283
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	10,864
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	946
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	12,027
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	1,207
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	9,290
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	994
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	6,747
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	1,493
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	11,980
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	1,840
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	4,251
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	4,286



TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	222
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,333
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	219
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,477
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	223
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,353
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	223
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,487
GEND_GBV_DSD	Number of people receiving post-GBV care	1,726
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,726
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,726
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	845
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	328
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	293
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	259
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART	2,200

	during TB treatment during the reporting period	
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	110
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,210
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	110
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	771
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	15,534
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	12,428
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	3,106
PMTCT_EID_DSD	Sum of Infant Age disaggregates	15,534
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	338,096
TX_CURR_DSD	Age/Sex: 15-19 Male	5,553
TX_CURR_DSD	Age/Sex: 15-19 Female	5,910
TX_CURR_DSD	Sum of age/sex disaggregates	11,463
TX_CURR_DSD	Age/Sex: <1	1,488
TX_CURR_DSD	Age/Sex: <1-9	13,399
TX_CURR_DSD	Age/Sex: 10-14 Male	7,022
TX_CURR_DSD	Age/Sex: 10-14 Female	7,101
TX_CURR_DSD	Age/Sex: 20-24 Male	4,761



TX_CURR_DSD	Age/Sex: 50+ Male	29,002
TX_CURR_DSD	Age/Sex: 20-24 Female	13,940
TX_CURR_DSD	Age/Sex: 50+ Female	28,020
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	20,829
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	5,372
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	33,296
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	11,856
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	38,721
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	20,077
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	50,301
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	41,448
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	43,211
TX_NEW_DSD	By Age/Sex: <1	448
TX_NEW_DSD	By Age/Sex: 1-9	1,225
TX_NEW_DSD	By Age/Sex: 10-14 Male	173
TX_NEW_DSD	By Age/Sex: 15-19 Male	2,081
TX_NEW_DSD	By Age/Sex: 20-24 Male	2,080
TX_NEW_DSD	By Age/Sex: 50+ Male	911
TX_NEW_DSD	By Age/Sex: 10-14 Female	179
TX_NEW_DSD	By Age/Sex: 15-19 Female	3,457
TX_NEW_DSD	By Age/Sex: 20-24 Female	4,412
TX_NEW_DSD	By Age/Sex: 50+ Female	71
TX_NEW_DSD	Sum of Age/Sex disaggregates	13,364
TX_NEW_DSD	Pregnancy status	8,080



TX_NEW_DSD	Breastfeeding status	2,167
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,241
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	1,619
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	2,710
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	3,853
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	2,635
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	4,059
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	3,313
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	7,744
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	220,629
TX_PVLS_DSD	Denominator: Indication: Routine	214,011
TX_PVLS_DSD	Denominator: Indication: Targeted	6,618
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	1,104
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	2,204
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	1,104
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	2,207
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	7,697
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	75,361





TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	7,832
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	123,120
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	74,521
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	75,219
TX_RET_DSD	Numerator by Status: Pregnant	1,220
TX_RET_DSD	Numerator by Status: Breastfeeding	2,248
TX_RET_DSD	Denominator by Status: Pregnant	1,374
TX_RET_DSD	Denominator by Status: Breastfeeding	2,171
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,581
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	40,653
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,594
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	28,693
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,679
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	40,951



	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,692
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28,897
HTS_SELF_DSD	HTS_SELF_N_DSD	26,443
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	2,126
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	373
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	1,738
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	692
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	2,696
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	467
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	2,154
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	868
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	540
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	467
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	4,310



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	868
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	238
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	231
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	2,151
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	428
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	238
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	231
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	2,151
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	428
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	150
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	137
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	1,271
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	254
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	97
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	93
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	873
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	174



HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	20,732
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	5,711
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	136,026
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	151,140
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	7,557
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	7,557
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	52,896
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	83,130
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	6,796
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	6,796
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	47,608
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	74,826
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	15,117
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	136,023
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	13,605
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	122,421
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	293,438
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	14,675
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	14,675
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	102,701



TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	161,387
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	293,438
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	117,366
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	176,072
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	261,166
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	2,930
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	29,052
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	290

**Implementing Mechanism Details**

<b>Mechanism ID: 18548</b>	<b>Mechanism Name: Technical Support for PMTCT and Comprehensive Prevention, Care, and Treatment</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18548	
<b>Mechanism Name:</b>	Technical Support for PMTCT and Comprehensive Prevention, Care, and Treatment	
<b>Prime Partner Name:</b>	University of California at San Francisco	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0



Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

**Implementing Mechanism Indicator Information**

(No data provided.)



**Implementing Mechanism Details**

<b>Mechanism ID: 18603</b>	<b>Mechanism Name: FISH</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Pact	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 18603</b> <b>Mechanism Name: FISH</b> <b>Prime Partner Name: Pact</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	135,286
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	30,494
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	12,760





Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	375,003

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	15,386
PP_PREV_DSD	Age/sex: 15-19 Male	1,078
PP_PREV_DSD	Age/sex: 20-24 Male	1,539
PP_PREV_DSD	Age/sex: 50+ Male	462
PP_PREV_DSD	Sum of Age/Sex disaggregates	3,079
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	3,076
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	3,846
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	3,846
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	1,539

### Implementing Mechanism Details

<b>Mechanism ID: 18649</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 18654</b>	<b>Mechanism Name: AIDS-free Malawi</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Approved



<b>Total All Funding Sources: 3,652,656</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,652,656</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,652,656

**Cross-Cutting Budget Attribution(s)**

Motor Vehicles: Purchased	144,900
---------------------------	---------

**Budget Code Information**

<b>Mechanism ID: 18654</b>		
<b>Mechanism Name: AIDS-free Malawi</b>		
<b>Prime Partner Name: John Snow Inc (JSI)</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	3,652,656
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	33,658
VMMC_CIRC_DSD	By Age: 10-14	6,761
VMMC_CIRC_DSD	By Age: 15-19	13,431
VMMC_CIRC_DSD	By Age: 20-24	6,830
VMMC_CIRC_DSD	By Age: 25-29	3,295
VMMC_CIRC_DSD	By Age: 50+	287
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	27,309
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	30,604
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	32,121
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	1,537
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	1,018
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	1,018
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	1,018
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	33,641
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	6,430
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	6,430
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	1,034



HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	5,567
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	4,762
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	15
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	4,073
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	5,252
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	30

### Implementing Mechanism Details

<b>Mechanism ID: 70175</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 70185</b>	<b>Mechanism Name: Baylor TSP</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Baylor College of Medicine Children's Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	



<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	200,000
Focus Area:	Post GBV Care
Sub Area:	Implementation
Water	100,000
Motor Vehicles: Purchased	18,000
Adolescent Girls and Young Women (AGYW)	200,000
Construction	225,000

**Budget Code Information**

<b>Mechanism ID: 70185</b>		
<b>Mechanism Name: Baylor TSP</b>		
<b>Prime Partner Name: Baylor College of Medicine Children's Foundation</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	756,023
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	824,729
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	540,020
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	2,446,363
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	200,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	4,397,130
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	1,337,899

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	11,317
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	135,393
PMTCT_ART_DSD	New on ART	4,174
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	7,143
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	135,393
PMTCT_STAT_DSD	Number of new ANC and L&D clients	142,513
PMTCT_STAT_DSD	By Age (Denominator): 10-14	333
PMTCT_STAT_DSD	By Age (Denominator): <15-19	32,134
PMTCT_STAT_DSD	By Age (Denominator): 20-24	50,140
PMTCT_STAT_DSD	By Age (Denominator): 50+	123
PMTCT_STAT_DSD	By Number of known positives: 10-14	22
PMTCT_STAT_DSD	By Number of known positives: 15-19	1,709
PMTCT_STAT_DSD	By Number of known positives: 20-24	2,666
PMTCT_STAT_DSD	By Number of known positives: 50+	6
PMTCT_STAT_DSD	By Number of new positives: 10-14	8
PMTCT_STAT_DSD	By Number of new positives: 15-19	979





PMTCT_STAT_DSD	By Number of new positives: 20-24	1,527
PMTCT_STAT_DSD	By Number of new positives: 50+	3
PMTCT_STAT_DSD	By Number of new negative: 10-14	287
PMTCT_STAT_DSD	By Number of new negative: 15-19	27,845
PMTCT_STAT_DSD	By Number of new negative: 20-24	43,438
PMTCT_STAT_DSD	By Number of new negative: 50+	100
PMTCT_STAT_DSD	By Age (Numerator): 10-14	312
PMTCT_STAT_DSD	By Age (Numerator): 15-19	30,535
PMTCT_STAT_DSD	By Age (Numerator): 20-24	47,632
PMTCT_STAT_DSD	By Age (Numerator): 50+	118
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	48,687
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	8,980
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	1,845
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	271
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	2,591
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	42,177
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	1,482
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	480
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	7,779
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	274
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	105
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	1,595
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	56
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult	17



	40-49, Female, Known at Entry Positive	
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	234
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	13
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	46,255
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	8,533
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	1,748
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	260
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	621,926
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	698
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	677
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	5,162
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	329
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	5,138
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	155
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	5,162
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	329
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	5,138



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	155
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	103
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	555
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	49
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	397
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	3,197
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	7,116
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	150
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	6,907
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	148
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	7,448
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	376
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	8,068
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	177
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	7,448
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	376



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	8,068
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	177
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	198
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	904
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	4,087
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	88
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	32,671
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	698
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	29,683
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	318
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	98
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	183
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	98



HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	183
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	218
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	213
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	4,308
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	707
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	3,028
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	385
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	4,308
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	707
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	3,028
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	385
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female,	39



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	783
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	184
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	122
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	978
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	67
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	8,174
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	312
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	12,826
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	488
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	20,788
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	774
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	3,414
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	69
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	3,302
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	66
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	23,671
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	1,347
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	30,970
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	719

HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	23,671
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	1,347
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	30,970
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	719
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	758
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	1,822
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	136
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	1,958
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	15,655
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	316
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	1,594
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	266
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	4,281
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	333
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	1,435
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	317
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	3,659



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	791
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	1,049
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	301
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	3,132
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	833
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	582
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	392
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	4,040
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	1,597
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	3,648
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	208
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	2,999
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	84
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	3,285
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	247
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	2,563
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	211





HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	2,386
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	228
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	2,197
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	220
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	1,343
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	299
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	2,834
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	423
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	657
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	5,806
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	252
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	4,915
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	101
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	5,230
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	286
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	4,211



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	259
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	3,808
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	269
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	3,595
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	273
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	2,143
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	351
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	4,634
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	507
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	23,912
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	848
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	5,371
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	184
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	3,543
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	126
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	42,299
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	1,617



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	355
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative	700
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	355
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	41
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	700
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	380
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	477
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	346
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	406
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	63
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	246



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	347
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	70
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	131
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	67
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	444
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	143
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	12
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	86
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	94
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	91
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	76
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	79
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	1



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	42
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	63
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	60
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	88
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	21,905
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	952
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	9,813
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	240
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	19,733
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	1,157
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	8,389
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	572
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	14,341



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	1,096
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	7,176
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	604
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	8,058
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	1,421
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	9,251
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	1,147
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,484
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,510
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	132
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,365
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	130
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	857
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	134
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total	1,371



	number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	132
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	873
GEND_GBVDSD	Number of people receiving post-GBV care	551
GEND_GBVDSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	347
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	203
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	204
GEND_GBVDSD	10-14, Female, Physical and/or Emotional Violence	66
GEND_GBVDSD	10-14, Female, Sexual Violence (Post-Rape Care)	20
GEND_GBVDSD	15-19, Female, Physical and/or Emotional Violence	110
GEND_GBVDSD	15-19, Female, Sexual Violence (Post-Rape Care)	84
GEND_GBVDSD	20-24, Female, Physical and/or Emotional Violence	171
GEND_GBVDSD	20-24, Female, Sexual Violence (Post-Rape Care)	99
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,208
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	53
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	665
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	64

	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	425
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	11,322
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	9,058
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	2,264
PMTCT_EID_DSD	Sum of Infant Age disaggregates	11,322
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	194
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	154
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	40
PMTCT_EID_TA	Sum of Infant Age disaggregates	194
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	239,096
TX_CURR_DSD	Age/Sex: 15-19 Male	3,502
TX_CURR_DSD	Age/Sex: 15-19 Female	3,463
TX_CURR_DSD	Sum of age/sex disaggregates	6,965
TX_CURR_DSD	Age/Sex: <1	1,278
TX_CURR_DSD	Age/Sex: <1-9	11,499
TX_CURR_DSD	Age/Sex: 10-14 Male	4,735
TX_CURR_DSD	Age/Sex: 10-14 Female	5,535
TX_CURR_DSD	Age/Sex: 20-24 Male	3,547
TX_CURR_DSD	Age/Sex: 50+ Male	18,918
TX_CURR_DSD	Age/Sex: 20-24 Female	9,158
TX_CURR_DSD	Age/Sex: 50+ Female	18,369
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29,	17,399





	Female, Positive	
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	3,897
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	25,814
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	8,816
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	27,942
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	14,105
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	33,830
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	27,289
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	34,284
TX_NEW_DSD	By Age/Sex: <1	376
TX_NEW_DSD	By Age/Sex: 1-9	1,397
TX_NEW_DSD	By Age/Sex: 10-14 Male	194
TX_NEW_DSD	By Age/Sex: 15-19 Male	1,754
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,754
TX_NEW_DSD	By Age/Sex: 50+ Male	526
TX_NEW_DSD	By Age/Sex: 10-14 Female	199
TX_NEW_DSD	By Age/Sex: 15-19 Female	3,188
TX_NEW_DSD	By Age/Sex: 20-24 Female	3,832
TX_NEW_DSD	By Age/Sex: 50+ Female	88
TX_NEW_DSD	Sum of Age/Sex disaggregates	11,535
TX_NEW_DSD	Pregnancy status	7,124
TX_NEW_DSD	Breastfeeding status	1,908
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	2,265
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	930



	Positive	
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	2,747
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	2,219
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	2,671
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	2,337
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	3,352
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	4,455
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	151,170
TX_PVLS_DSD	Denominator: Indication: Routine	146,633
TX_PVLS_DSD	Denominator: Indication: Targeted	4,537
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	756
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,511
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	756
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,511
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	5,002
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	50,052
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	5,504
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	86,078



TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	48,383
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	48,805
TX_RET_DSD	Numerator by Status: Pregnant	952
TX_RET_DSD	Numerator by Status: Breastfeeding	1,483
TX_RET_DSD	Denominator by Status: Pregnant	963
TX_RET_DSD	Denominator by Status: Breastfeeding	2,413
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,191
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19,357
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,202
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	24,633
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,268
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19,474
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	2,281



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	24,782
HTS_SELF_DSD	HTS_SELF_N_DSD	18,095
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	1,455
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	255
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	1,190
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	474
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	1,845
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	320
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	1,474
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	594
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	369
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	320
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	2,949
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	594
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	163



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	158
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	1,472
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	292
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	163
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	158
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	1,472
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	292
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	103
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	94
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	870
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	174
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	66
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	64
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	597
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	119
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	14,187
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	3,908
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of	690



	Isoniazid Preventive Therapy (IPT) during the reporting period	
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	764
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	38
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	38
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	267
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	421
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	35
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	35
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	241
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	379
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	75
TB_PREV_DSD	TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	689
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	69
TB_PREV_DSD	TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	621
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	234,869
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	11,745
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	11,745
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	82,206
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	129,173
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	234,869



TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	93,947
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	140,922
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	209,032
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	2,349
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	23,253
TX_TB_DSD	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	235

### Implementing Mechanism Details

Mechanism ID: 70186	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 70188	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 70189	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 70190	TBD: Yes
REDACTED	



### Implementing Mechanism Details

<b>Mechanism ID: 70191</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 80043</b>	<b>Mechanism Name: Global Health Supply Chain Program (GHSC) - HIV Rapid Test Kits (RTKs)</b>	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: Remote Medical International		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

<b>Total All Funding Sources: 157,500</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 157,500</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	157,500

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	<b>80043</b>	
<b>Mechanism Name:</b>	<b>Global Health Supply Chain Program (GHSC) - HIV Rapid Test Kits (RTKs)</b>	
<b>Prime Partner Name:</b>	<b>Remote Medical International</b>	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Approved



Prevention	HVCT	157,500

### Implementing Mechanism Indicator Information

(No data provided.)



**Agency Information - Costs of Doing Business**  
**U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services			208,979	208,979	0	208,979
ICASS			640,954	640,954	0	640,954
Management Meetings/Professional Development			300,000	300,000	0	300,000
Non-ICASS Administrative Costs			145,728	145,728	0	145,728
Staff Program Travel		0	697,568	697,568	0	697,568
USG Staff Salaries and Benefits - Internationally Recruited		0	1,868,947	1,868,947	0	1,868,947
USG Staff Salaries and Benefits - Locally Recruited		0	1,216,604	1,216,604	0	1,216,604
<b>Total</b>	<b>0</b>	<b>0</b>	<b>5,078,780</b>	<b>5,078,780</b>	<b>0</b>	<b>5,078,780</b>



### U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		4,000		4,000	0	4,000
ICASS		15,000		15,000	0	15,000
Management Meetings/Professional Development		7,550		7,550	0	7,550
Non-ICASS Administrative Costs		4,000		4,000	0	4,000
Non-ICASS Motor Vehicles		3,000		3,000	0	3,000
Staff Program Travel		20,000		20,000	0	20,000
USG Staff Salaries and Benefits - Internationally Recruited				0	0	0
USG Staff Salaries and Benefits - Locally Recruited		20,432		20,432	69,568	90,000
<b>Total</b>	<b>0</b>	<b>73,982</b>	<b>0</b>	<b>73,982</b>	<b>69,568</b>	<b>143,550</b>



### U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing	780,699			780,699	0	780,699
Computers/IT Services		185,511		185,511	0	185,511
ICASS	731,801	396,244		1,128,045	0	1,128,045
Institutional Contractors	0	565,355		565,355	0	565,355
Management Meetings/Professional Development		437,750		437,750	0	437,750
Non-ICASS Administrative Costs		375,370		375,370	0	375,370
Staff Program Travel	0	248,800		248,800	0	248,800
USG Staff Salaries and Benefits - Internationally Recruited	0	2,254,213		2,254,213	0	2,254,213
USG Staff Salaries and Benefits - Locally Recruited	0	1,570,524		1,570,524	0	1,570,524



<b>Total</b>	<b>1,512,500</b>	<b>6,033,767</b>	<b>0</b>	<b>7,546,267</b>	<b>0</b>	<b>7,546,267</b>
--------------	------------------	------------------	----------	------------------	----------	------------------

**U.S. Department of State**

<b>Agency Cost of Doing Business</b>	<b>GAP</b>	<b>GHP-State</b>	<b>GHP-USAID</b>	<b>Funding Source Total</b>	<b>Applied Pipeline</b>	<b>Total All Funding Sources and Applied Pipeline Amount</b>
Computers/IT Services		0		0	23,400	23,400
ICASS		147,939		147,939	0	147,939
Institutional Contractors				0	0	0
Management Meetings/Professional Development		0		0	136,400	136,400
Non-ICASS Administrative Costs		0		0	61,000	61,000
Peace Corps Volunteer Costs				0	0	0
Staff Program Travel		0		0	12,600	12,600
USG Staff Salaries and Benefits - Internationally Recruited		477,083		477,083	0	477,083
USG Staff Salaries and Benefits -		0		0	134,000	134,000



Locally Recruited						
<b>Total</b>	<b>0</b>	<b>625,022</b>	<b>0</b>	<b>625,022</b>	<b>367,400</b>	<b>992,422</b>

**U.S. Peace Corps**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Institutional Contractors				0	0	0
Non-ICASS Administrative Costs		191,677		191,677	0	191,677
Peace Corps Volunteer Costs		1,043,724		1,043,724	217,960	1,261,684
Staff Program Travel		43,086		43,086	0	43,086
USG Staff Salaries and Benefits - Internationally Recruited				0	0	0
USG Staff Salaries and Benefits - Locally Recruited		230,046		230,046	0	230,046
<b>Total</b>	<b>0</b>	<b>1,508,533</b>	<b>0</b>	<b>1,508,533</b>	<b>217,960</b>	<b>1,726,493</b>

Approved

